JPWO2019175806A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019175806A5 JPWO2019175806A5 JP2020549031A JP2020549031A JPWO2019175806A5 JP WO2019175806 A5 JPWO2019175806 A5 JP WO2019175806A5 JP 2020549031 A JP2020549031 A JP 2020549031A JP 2020549031 A JP2020549031 A JP 2020549031A JP WO2019175806 A5 JPWO2019175806 A5 JP WO2019175806A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- hydrochloride
- binding fragment
- bispecific antibody
- mospd2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 114
- 108091007172 antigens Proteins 0.000 claims description 114
- 102000038129 antigens Human genes 0.000 claims description 114
- 108090001123 antibodies Proteins 0.000 claims description 84
- 102000004965 antibodies Human genes 0.000 claims description 84
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 102100013484 MOSPD2 Human genes 0.000 claims description 32
- 101710017292 MOSPD2 Proteins 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 30
- 241000701806 Human papillomavirus Species 0.000 claims description 24
- -1 Carmustine-Taxol Chemical compound 0.000 claims description 22
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 20
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 20
- 229960005486 vaccines Drugs 0.000 claims description 18
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 16
- 229960004630 Chlorambucil Drugs 0.000 claims description 14
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 14
- 229960005243 carmustine Drugs 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 claims description 12
- 229960004338 Leuprorelin Drugs 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 229960000485 methotrexate Drugs 0.000 claims description 12
- 210000004027 cells Anatomy 0.000 claims description 11
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- 229940089022 Leuprolide Acetate Drugs 0.000 claims description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 10
- 229960001592 Paclitaxel Drugs 0.000 claims description 10
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 10
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 10
- 108010071919 Bispecific Antibodies Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 8
- 230000035693 Fab Effects 0.000 claims description 8
- 229960002949 Fluorouracil Drugs 0.000 claims description 8
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 8
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 8
- 229960004857 Mitomycin Drugs 0.000 claims description 8
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 8
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 8
- 229960002092 busulfan Drugs 0.000 claims description 8
- BIFMNMPSIYHKDN-FJXQXJEOSA-N dexrazoxane hydrochloride Chemical compound [H+].[Cl-].C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BIFMNMPSIYHKDN-FJXQXJEOSA-N 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002105 nanoparticle Substances 0.000 claims description 8
- 229960001796 sunitinib Drugs 0.000 claims description 8
- 229930003347 taxol Natural products 0.000 claims description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 7
- 229960005420 Etoposide Drugs 0.000 claims description 7
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 7
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 claims description 6
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 6
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 6
- 229960002756 Azacitidine Drugs 0.000 claims description 6
- 229960004562 Carboplatin Drugs 0.000 claims description 6
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 6
- BFSMGDJOXZAERB-UHFFFAOYSA-N Dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 6
- 229960004102 Dexrazoxane hydrochloride Drugs 0.000 claims description 6
- 229960004679 Doxorubicin Drugs 0.000 claims description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 6
- 229960001101 Ifosfamide Drugs 0.000 claims description 6
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims description 6
- 210000004693 NK cell Anatomy 0.000 claims description 6
- FAQDUNYVKQKNLD-UHFFFAOYSA-N Olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 6
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 6
- 108010001645 Rituximab Proteins 0.000 claims description 6
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims description 6
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 6
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 6
- 229960000237 Vorinostat Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 229960002932 anastrozole Drugs 0.000 claims description 6
- 229960003005 axitinib Drugs 0.000 claims description 6
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 6
- 229960002938 bexarotene Drugs 0.000 claims description 6
- 229960002465 dabrafenib Drugs 0.000 claims description 6
- 229960000255 exemestane Drugs 0.000 claims description 6
- 229960000390 fludarabine Drugs 0.000 claims description 6
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007943 implant Substances 0.000 claims description 6
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 6
- 229960001428 mercaptopurine Drugs 0.000 claims description 6
- 229960000572 olaparib Drugs 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 229960004641 rituximab Drugs 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 6
- 229960002293 Leucovorin Calcium Drugs 0.000 claims description 5
- 229960003048 Vinblastine Drugs 0.000 claims description 5
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims description 5
- 235000008207 calcium folinate Nutrition 0.000 claims description 5
- 239000011687 calcium folinate Substances 0.000 claims description 5
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims description 5
- 229960003862 vemurafenib Drugs 0.000 claims description 5
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 5
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims description 4
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 claims description 4
- BWTNNZPNKQIADY-UHFFFAOYSA-N 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide;hydrochloride Chemical compound Cl.C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 BWTNNZPNKQIADY-UHFFFAOYSA-N 0.000 claims description 4
- IKWTVSLWAPBBKU-UHFFFAOYSA-N A1010_SIAL Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 claims description 4
- 229960003272 ASPARAGINASE Drugs 0.000 claims description 4
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 4
- 102000015790 Asparaginase Human genes 0.000 claims description 4
- 108010024976 Asparaginase Proteins 0.000 claims description 4
- 229940120638 Avastin Drugs 0.000 claims description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229960003265 Epirubicin Hydrochloride Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960005144 Gemcitabine hydrochloride Drugs 0.000 claims description 4
- 229960000779 Irinotecan hydrochloride Drugs 0.000 claims description 4
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 4
- 229960004635 Mesna Drugs 0.000 claims description 4
- 206010027476 Metastasis Diseases 0.000 claims description 4
- 229960005163 Netupitant Drugs 0.000 claims description 4
- 229960002450 Ofatumumab Drugs 0.000 claims description 4
- LZMPYSIUWPEIRA-XFXZXTDPSA-N Ofatumumab Chemical compound N1=C2C=3COCCC=3N=CC2=N\C1=C1\NOC=C1 LZMPYSIUWPEIRA-XFXZXTDPSA-N 0.000 claims description 4
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 4
- 229960005492 Pazopanib Hydrochloride Drugs 0.000 claims description 4
- YIQPUIGJQJDJOS-UHFFFAOYSA-N Plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims description 4
- 229960002169 Plerixafor Drugs 0.000 claims description 4
- 229960001586 Procarbazine Hydrochloride Drugs 0.000 claims description 4
- RWRDJVNMSZYMDV-UHFFFAOYSA-L Radium chloride Chemical compound [Cl-].[Cl-].[Ra+2] RWRDJVNMSZYMDV-UHFFFAOYSA-L 0.000 claims description 4
- 108091008153 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 4
- 229960002190 Topotecan Hydrochloride Drugs 0.000 claims description 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010010691 Trastuzumab Proteins 0.000 claims description 4
- 229960004528 Vincristine Drugs 0.000 claims description 4
- 229960002110 Vincristine Sulfate Drugs 0.000 claims description 4
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 claims description 4
- 229960002736 afatinib dimaleate Drugs 0.000 claims description 4
- USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 claims description 4
- 229960002749 aminolevulinic acid Drugs 0.000 claims description 4
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229960001372 aprepitant Drugs 0.000 claims description 4
- 229960002594 arsenic trioxide Drugs 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229940063519 doxorubicin hydrochloride liposome Drugs 0.000 claims description 4
- 229960005304 fludarabine phosphate Drugs 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 claims description 4
- 229960001507 ibrutinib Drugs 0.000 claims description 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 4
- 229960002411 imatinib Drugs 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- WAXQNWCZJDTGBU-UHFFFAOYSA-N netupitant Chemical compound C=1N=C(N2CCN(C)CC2)C=C(C=2C(=CC=CC=2)C)C=1N(C)C(=O)C(C)(C)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WAXQNWCZJDTGBU-UHFFFAOYSA-N 0.000 claims description 4
- 108010052070 ofatumumab Proteins 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- 229960005184 panobinostat Drugs 0.000 claims description 4
- MQHIQUBXFFAOMK-UHFFFAOYSA-N pazopanib hydrochloride Chemical compound Cl.C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 MQHIQUBXFFAOMK-UHFFFAOYSA-N 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 108010026276 pembrolizumab Proteins 0.000 claims description 4
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229960002183 ponatinib hydrochloride Drugs 0.000 claims description 4
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229960000235 temsirolimus Drugs 0.000 claims description 4
- 229960004066 trametinib Drugs 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- 210000004881 tumor cells Anatomy 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- 229960002760 ziv-aflibercept Drugs 0.000 claims description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N Crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 3
- 210000002540 Macrophages Anatomy 0.000 claims description 3
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 3
- 229960005061 crizotinib Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- JVHPTYWUBOQMBP-RVFAQHLVSA-N (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 JVHPTYWUBOQMBP-RVFAQHLVSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- TYEXNVNUZXJNBN-YYADALCUSA-N 3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid Chemical compound O=C1C(N\N=C/2C(C(=CC=C\2)C=2C=C(C=CC=2)C(O)=O)=O)=C(C)NN1C1=CC=C(C)C(C)=C1 TYEXNVNUZXJNBN-YYADALCUSA-N 0.000 claims description 2
- AQGAPDRYTMVBHY-YAQKJFNRSA-O ABVD protocol Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C AQGAPDRYTMVBHY-YAQKJFNRSA-O 0.000 claims description 2
- 102100001249 ALB Human genes 0.000 claims description 2
- 101710027066 ALB Proteins 0.000 claims description 2
- 229940028652 Abraxane Drugs 0.000 claims description 2
- 229940035938 Adcetris Drugs 0.000 claims description 2
- 229940009456 Adriamycin Drugs 0.000 claims description 2
- 229940060265 Aldara Drugs 0.000 claims description 2
- 108010090838 Alemtuzumab Proteins 0.000 claims description 2
- 229940078010 Arimidex Drugs 0.000 claims description 2
- 229940087620 Aromasin Drugs 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N Bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940108502 BiCNU Drugs 0.000 claims description 2
- 229940112133 Busulfex Drugs 0.000 claims description 2
- 101700024689 CD2 Proteins 0.000 claims description 2
- 102100019461 CD28 Human genes 0.000 claims description 2
- 101700033362 CD28 Proteins 0.000 claims description 2
- 101700066525 CD5 Proteins 0.000 claims description 2
- XMJCOTSQMHGIPF-SNSGICDFSA-N COPP protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.CNNCC1=CC=C(C(=O)NC(C)C)C=C1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 XMJCOTSQMHGIPF-SNSGICDFSA-N 0.000 claims description 2
- 102100006435 CSF3 Human genes 0.000 claims description 2
- 229940088954 Camptosar Drugs 0.000 claims description 2
- 229960004117 Capecitabine Drugs 0.000 claims description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 2
- PGMBSCDPACPRSG-SCSDYSBLSA-N Capiri Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PGMBSCDPACPRSG-SCSDYSBLSA-N 0.000 claims description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N Carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
- 229940097647 Casodex Drugs 0.000 claims description 2
- 229940088547 Cosmegen Drugs 0.000 claims description 2
- 241001541138 Cypho Species 0.000 claims description 2
- 229940050303 Cyramza Drugs 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229940059359 Dacogen Drugs 0.000 claims description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 2
- 229960000975 Daunorubicin Drugs 0.000 claims description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 2
- 229960002272 Degarelix Drugs 0.000 claims description 2
- MEUCPCLKGZSHTA-XYAYPHGZSA-N Degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 claims description 2
- 108010043242 Denosumab Proteins 0.000 claims description 2
- 229960000605 Dexrazoxane Drugs 0.000 claims description 2
- 230000036947 Dissociation constant Effects 0.000 claims description 2
- 229940115080 Doxil Drugs 0.000 claims description 2
- 229940014684 Erivedge Drugs 0.000 claims description 2
- 229960001433 Erlotinib Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 229960005073 Erlotinib Hydrochloride Drugs 0.000 claims description 2
- 241000588698 Erwinia Species 0.000 claims description 2
- 229940085363 Evista Drugs 0.000 claims description 2
- 101700079540 FAS Proteins 0.000 claims description 2
- 102100016439 FAS Human genes 0.000 claims description 2
- 102100015541 FCGR3A Human genes 0.000 claims description 2
- 101710044656 FCGR3A Proteins 0.000 claims description 2
- 101710044657 FCGR3B Proteins 0.000 claims description 2
- 229940087861 Faslodex Drugs 0.000 claims description 2
- 229940087476 Femara Drugs 0.000 claims description 2
- 229960004177 Filgrastim Drugs 0.000 claims description 2
- 108010029961 Filgrastim Proteins 0.000 claims description 2
- 229940064300 Fluoroplex Drugs 0.000 claims description 2
- 229960002258 Fulvestrant Drugs 0.000 claims description 2
- 108010091266 Gemtuzumab Proteins 0.000 claims description 2
- 229940020967 Gemzar Drugs 0.000 claims description 2
- 229940080856 Gleevec Drugs 0.000 claims description 2
- 229960002913 Goserelin Drugs 0.000 claims description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 2
- 229940022353 Herceptin Drugs 0.000 claims description 2
- HYFHYPWGAURHIV-JFIAXGOJSA-N Homoharringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 claims description 2
- 229940088013 Hycamtin Drugs 0.000 claims description 2
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 claims description 2
- 102100008763 IFNA2 Human genes 0.000 claims description 2
- 229940061301 Ibrance Drugs 0.000 claims description 2
- 229940049235 Iclusig Drugs 0.000 claims description 2
- 229940099279 Idamycin Drugs 0.000 claims description 2
- 229960001176 Idarubicin Hydrochloride Drugs 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- 229940090411 Ifex Drugs 0.000 claims description 2
- 229960003685 Imatinib mesylate Drugs 0.000 claims description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 2
- 108010089187 Ipilimumab Proteins 0.000 claims description 2
- 229940084651 Iressa Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229940011083 Istodax Drugs 0.000 claims description 2
- 229940045773 Jakafi Drugs 0.000 claims description 2
- 102100012223 KLRK1 Human genes 0.000 claims description 2
- 101710036390 KLRK1 Proteins 0.000 claims description 2
- 229940022039 Keytruda Drugs 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- 229940008250 Leuprolide Drugs 0.000 claims description 2
- 108010000817 Leuprolide Proteins 0.000 claims description 2
- 229940100352 Lynparza Drugs 0.000 claims description 2
- 229960004296 Megestrol Acetate Drugs 0.000 claims description 2
- 229940083118 Mekinist Drugs 0.000 claims description 2
- 229940101533 Mesnex Drugs 0.000 claims description 2
- UWYXLGUQQFPJRI-UHFFFAOYSA-N N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 UWYXLGUQQFPJRI-UHFFFAOYSA-N 0.000 claims description 2
- 229940080607 Nexavar Drugs 0.000 claims description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
- 229940085033 Nolvadex Drugs 0.000 claims description 2
- 229950007318 OZOGAMICIN Drugs 0.000 claims description 2
- 229940098444 Opdivo Drugs 0.000 claims description 2
- 229960004390 Palbociclib Drugs 0.000 claims description 2
- AHJRHEGDXFFMBM-UHFFFAOYSA-N Palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 2
- 108010061219 Panitumumab Proteins 0.000 claims description 2
- 229940106366 Pegintron Drugs 0.000 claims description 2
- 229940039551 Perjeta Drugs 0.000 claims description 2
- UNQNIRQQBJCMQR-UHFFFAOYSA-N Phosphorine Chemical compound C1=CC=PC=C1 UNQNIRQQBJCMQR-UHFFFAOYSA-N 0.000 claims description 2
- 229940063179 Platinol Drugs 0.000 claims description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N Ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 2
- 229940087463 Proleukin Drugs 0.000 claims description 2
- 229940092597 Prolia Drugs 0.000 claims description 2
- 229940021945 Promacta Drugs 0.000 claims description 2
- 229940034080 Provenge Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960004622 Raloxifene Drugs 0.000 claims description 2
- 229940061969 Rheumatrex Drugs 0.000 claims description 2
- HNMATTJJEPZZMM-BPKVFSPJSA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2S,5Z,9R,13E)-13-[2-[[4-[(2E)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 claims description 2
- INIBXSLTWQVIHS-ASACRTLUSA-O Stanford V protocol Chemical compound ClCCN(C)CCCl.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3C(O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C INIBXSLTWQVIHS-ASACRTLUSA-O 0.000 claims description 2
- 229940034785 Sutent Drugs 0.000 claims description 2
- 229940022873 Synribo Drugs 0.000 claims description 2
- 229940014598 TAC Drugs 0.000 claims description 2
- 101710040448 TNFRSF4 Proteins 0.000 claims description 2
- 101710040535 TNFRSF9 Proteins 0.000 claims description 2
- 229940081616 Tafinlar Drugs 0.000 claims description 2
- 229940120982 Tarceva Drugs 0.000 claims description 2
- 229940099419 Targretin Drugs 0.000 claims description 2
- 229940069905 Tasigna Drugs 0.000 claims description 2
- 229940063683 Taxotere Drugs 0.000 claims description 2
- 229940061353 Temodar Drugs 0.000 claims description 2
- 229940100411 Torisel Drugs 0.000 claims description 2
- 229940066958 Treanda Drugs 0.000 claims description 2
- 229940086984 Trisenox Drugs 0.000 claims description 2
- 229940022919 Unituxin Drugs 0.000 claims description 2
- ATCJTYORYKLVIA-SRXJVYAUSA-N Vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 claims description 2
- 229940058865 Vectibix Drugs 0.000 claims description 2
- 229940099039 Velcade Drugs 0.000 claims description 2
- 229940065658 Vidaza Drugs 0.000 claims description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N Vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 claims description 2
- 229940055760 Yervoy Drugs 0.000 claims description 2
- 229940036061 Zaltrap Drugs 0.000 claims description 2
- 229940034727 Zelboraf Drugs 0.000 claims description 2
- 229940033942 Zoladex Drugs 0.000 claims description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 2
- 229940002005 Zometa Drugs 0.000 claims description 2
- 229940051084 Zytiga Drugs 0.000 claims description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N [(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]azanium;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims description 2
- 229960004103 abiraterone acetate Drugs 0.000 claims description 2
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 229940050528 albumin Drugs 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 2
- 229960002707 bendamustine Drugs 0.000 claims description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- 229960002438 carfilzomib Drugs 0.000 claims description 2
- 108010021331 carfilzomib Proteins 0.000 claims description 2
- 229960002448 dasatinib Drugs 0.000 claims description 2
- 229960003603 decitabine Drugs 0.000 claims description 2
- 229960001251 denosumab Drugs 0.000 claims description 2
- 229960004497 dinutuximab Drugs 0.000 claims description 2
- 108091003638 dinutuximab Proteins 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960000578 gemtuzumab Drugs 0.000 claims description 2
- 229960004859 glucarpidase Drugs 0.000 claims description 2
- 108010049491 glucarpidase Proteins 0.000 claims description 2
- 229960002751 imiquimod Drugs 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 230000002601 intratumoral Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- 229960001320 lapatinib ditosylate Drugs 0.000 claims description 2
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 2
- 229960001346 nilotinib Drugs 0.000 claims description 2
- 229960003347 obinutuzumab Drugs 0.000 claims description 2
- 108010045555 obinutuzumab Proteins 0.000 claims description 2
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229960001131 ponatinib Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229960004836 regorafenib Drugs 0.000 claims description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 2
- 229960003452 romidepsin Drugs 0.000 claims description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 2
- 229960000215 ruxolitinib Drugs 0.000 claims description 2
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 2
- 108010056973 siltuximab Proteins 0.000 claims description 2
- 229960003323 siltuximab Drugs 0.000 claims description 2
- BKBBTCORRZMASO-UHFFFAOYSA-M sodium;2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC([O-])=O)C(O)=O)C=C1 BKBBTCORRZMASO-UHFFFAOYSA-M 0.000 claims description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M sodium;2-sulfanylethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- 229960004449 vismodegib Drugs 0.000 claims description 2
- 229960004276 zoledronic acid Drugs 0.000 claims description 2
- 229940053867 Xeloda Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 4
- 102100016020 IFNG Human genes 0.000 description 3
- 101700086956 IFNG Proteins 0.000 description 3
- 210000001744 T-Lymphocytes Anatomy 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 102100005832 CD69 Human genes 0.000 description 2
- 101700080416 CD69 Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004936 stimulating Effects 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960002166 Vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N VinorelbineTartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 229940061261 Zolinza Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
Description
ããã€ãã®å®æœåœ¢æ
ã§ã¯ãæ¬çºæã¯ãïŒïœïŒæ¬æ现æžã«èšèŒã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬æ现æžã«èšèŒã®å»è¬çµæç©ãããã³ïŒïœïœïŒäœ¿çšèª¬ææžãå«ããããã«é¢ããã
[æ¬çºæ1001]
ïŒïœïŒïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã«å¯Ÿãã1ã€ä»¥äžã®æåçµåãã¡ã€ã³ãããã³ïŒïœïœïŒïŒŽçŽ°èãŸãã¯ïŒ®ïŒ«çŽ°èç¹ç°çå容äœååã«å¯Ÿãã1ã€ä»¥äžã®æåçµåãã¡ã€ã³ãå«ããäºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1002]
åèšïŒŽçŽ°èãŸãã¯ïŒ®ïŒ«çŽ°èç¹ç°çå容äœååãã3ã现èå容äœïŒïŒŽïŒ£ïŒ²ïŒã28ã16ã2ãïœ40ã4ïŒ1ã2ã5ããŸãã¯ïŒ£ïŒ€95ã§ãããæ¬çºæ1001ã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1003]
ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã«å¯Ÿããåèš1ã€ä»¥äžã®æåçµåãã¡ã€ã³ããæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®ïŒŠïœïœãïœïœâãïŒïœïœâïŒ
2
ãïœãïœïœïŒŠïœãïœïœïŒŠïœæçãééå¯å€é åã軜éå¯å€é åãçžè£æ§æ±ºå®é åïŒïŒ£ïŒ€ïŒ²ïŒãéé1ãéé2ãéé3ã軜é1ã軜é2ããŸãã¯è»œé3ã§ãããæ¬çºæ1001ãŸãã¯1002ã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1004]
åèšïŒŽçŽ°èãŸãã¯ïŒ®ïŒ«çŽ°èç¹ç°çå容äœååã3ã§ãããããã³ïŒ£ïŒ€3ã«å¯Ÿãã1ã€ä»¥äžã®æåçµåãã¡ã€ã³ããæ3æäœãŸãã¯ãã®æåçµåæçã®ïŒŠïœïœãïœïœâãïŒïœïœâïŒ
2
ãïœãïœïœïŒŠïœãïœïœïŒŠïœæçãééå¯å€é åã軜éå¯å€é åããéé1ãéé2ãéé3ã軜é1ã軜é2ããŸãã¯è»œé3ã§ãããæ¬çºæ1001ïœ1003ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1005]
以äžã®æåçµåãã¡ã€ã³ïŒ
ïŒïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒããã³
ïŒïœïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é å
ã®1ã€ä»¥äžãå«ããæ¬çºæ1001ïœ1004ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1006]
以äžã®æåçµåãã¡ã€ã³ïŒ
ïŒïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒããã³
ïŒïœïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é å
ã®1ã€ä»¥äžãå«ããæ¬çºæ1001ïœ1005ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1007]
以äžã®æåçµåãã¡ã€ã³ïŒ
ïŒïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒ
ïŒïœïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é åïŒ
ïŒïœïœïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒããã³
ïŒïœïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é å
ãå«ããæ¬çºæ1001ïœ1006ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1008]
åèšæåçµåãã¡ã€ã³ã®1ã€ä»¥äžããããããªã³ã«ãŒã«ãã£ãŠé£çµãããŠãããæ¬çºæ1001ïœ1007ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1009]
å°ãªããšã1ã€ã®æåçµåãã¡ã€ã³ãããã§ãããæ¬çºæ1001ïœ1008ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1010]
å°ãªããšã1ã€ã®æåçµåãã¡ã€ã³ãããåãããŠãããæ¬çºæ1001ïœ1008ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1011]
åèšäºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçãäžæ¬éããªããããã§ãããæ¬çºæ1001ïœ1010ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1012]
åèšäºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçããçŽ60ïŒ000ãã«ãã³ä»¥äžã®ååéãæãããæ¬çºæ1001ïœ1011ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1013]
åèšäºéç¹ç°æ§æäœããããããã£ããã€ã¢ããã£ããã¥ãªããã£ãïœïœïœïœïŒïœïœãäºäŸ¡æäœãäºéç¹ç°æ§ïŒŽçŽ°èãšã³ã²ãŒãžã£ïŒïŒ¢ïœïŒŽïŒ¥ïŒãäºé芪åæ§åæšçåïŒïŒ€ïŒ¡ïŒ²ïŒŽïŒãããªãã«ããã£ãããæäœãïœïœïŒ¢ïœããããã£ãã€ã³ãã©ããã£ããŸãã¯ã¯ã¢ãããŒãã§ãããæ¬çºæ1001ïœ1012ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1014]
åèšäºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçããçŽ10
ïŒ6
ïŒïœçŽ10
ïŒ12
ïŒã®å¹³è¡¡è§£é¢å®æ°ïŒïŒ«

ïŒã§ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ããã³ïŒãŸãã¯ïŒ£ïŒ€3ã«ç¹ç°çã«çµåãããæ¬çºæ1001ïœ1013ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1015]
åèšäºéç¹ç°æ§æäœãããã¯æåçµåæçããŸãã¯ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã«å¯Ÿãã1ã€ä»¥äžã®æåçµåãã¡ã€ã³ããé
åçªå·1ïœ4ã®1ã€ä»¥äžããŸãã¯ãã®æ©èœçå€ç°äœã«ç¹ç°çã«çµåãããæ¬çºæ1001ïœ1014ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1016]
åèšäºéç¹ç°æ§æäœãããã¯æåçµåæçããŸãã¯ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã«å¯Ÿãã1ã€ä»¥äžã®æåçµåãã¡ã€ã³ããé
åçªå·5ïœ8ã®1ã€ä»¥äžããŸãã¯ãã®æ©èœçå€ç°äœã«ãã£ãŠã³ãŒããããããªããããã«ç¹ç°çã«çµåãããæ¬çºæ1001ïœ1015ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1017]
åèšäºéç¹ç°æ§æäœãããã¯æåçµåæçããŸãã¯ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã«å¯Ÿãã1ã€ä»¥äžã®æåçµåãã¡ã€ã³ããçŽ10
ïŒ6
ïŒïœçŽ10
ïŒ12
ïŒã®ïŒ«

ã§ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã«ç¹ç°çã«çµåãããæ¬çºæ1001ïœ1016ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã
[æ¬çºæ1018]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçãšãè¬åŠçã«èš±å®¹ãããæ
äœãšãå«ãå»è¬çµæç©ã
[æ¬çºæ1019]
å
šèº«æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1020]
å±ææäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1021]
çµå£æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1022]
çµéŒ»æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1023]
è
¹è
å
æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1024]
è
«çå
æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1025]
éèå
æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1026]
çèå
æäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1027]
ç®äžæäžã«é©ãããæ¬çºæ1018ã®å»è¬çµæç©ã
[æ¬çºæ1028]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ããçãæ²»çãŸãã¯äºé²ããã®ã«æå¹ãªéã§å¯Ÿè±¡ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããçãæ²»çãŸãã¯äºé²ããæ¹æ³ã
[æ¬çºæ1029]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ããç転移ãæ²»çãŸãã¯äºé²ããã®ã«æå¹ãªéã§å¯Ÿè±¡ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããç転移ãæ²»çãŸãã¯äºé²ããæ¹æ³ã
[æ¬çºæ1030]
åèšå¯Ÿè±¡ã«æå¹éã®æçå€ãæäžããããšãããã«å«ããæ¬çºæ1028ãŸãã¯1029ã®æ¹æ³ã
[æ¬çºæ1031]
åèšæçå€ããã¢ãã©ããã³é
¢é
žãšã¹ãã«ãã¢ããã¬ããµãŒãïŒã¡ããã¬ããµãŒãïŒãã¢ãã©ããµã³ïŒãã¯ãªã¿ãã»ã«ã¢ã«ããã³å®å®åããç²å補å€ïŒãããïŒïŒ°ïŒ£ããïŒïŒŽãã¢ãã»ããªã¹ïŒãã¬ã³ããã·ãããããã³ïŒããã¢ããã©ã¹ããºãããšã ã¿ã³ã·ã³ãã¢ããªã¢ãã€ã·ã³ïŒå¡©é
žãããœã«ãã·ã³ïŒãã¢ãã«ã·ã«ïŒãã«ãªããŠã©ã·ã«ïŒããžãã¬ã€ã³é
žã¢ãã¡ããããã¢ãã£ãããŒã«ïŒãšãããªã ã¹ïŒãã¢ãã³ãŒãªïŒãããã¿ã³ãããã³ãããã»ããã³å¡©é
žå¡©ïŒãã¢ã«ãã©ïŒã€ããã¢ãïŒãã¢ã«ãã¹ãã€ãã³ãã¢ã¬ã ããºãããã¢ãªã ã¿ïŒãã¡ãã¬ãã»ãäºãããªãŠã ïŒãã¢ããã·ïŒãããã»ããã³å¡©é
žå¡©ïŒãã¢ã³ãã¯ããªã³ïŒïŒ¡ïœïœïœïœïœïœïœïœïœïœïŒïŒã¯ãã©ã ãã·ã«ïŒãã¢ã³ãã¯ããªã³ïŒïŒ¡ïœïœïœïœïœïœïœïœïœïŒïŒã¯ãã©ã ãã·ã«ïŒãã¢ããã¬ããªã³é
žãã¢ãã¹ãããŸãŒã«ãã¢ãã¬ãã¿ã³ããã¢ã¬ãã£ã¢ïŒããããã³é
žäºãããªãŠã ïŒãã¢ãªãããã¯ã¹ïŒã¢ãã¹ãããŸãŒã«ïŒãã¢ããã·ã³ïŒãšãã»ã¡ã¹ã¿ã³ïŒãã¢ã©ãã³ïŒãã©ã©ãã³ïŒãäžé
žåãçŽ ãã¢ãŒãŒã©ïŒãªãã¡ãã ããïŒãã¢ã¹ãã©ã®ããŒãŒãšã«ãŠã£ãã¢ã¯ãªãµã³ããïŒïŒ¡ïœïœïœïœïœïœïœïœïœïœïœ
ïœïœïœïœïœïœ ïœïœïœïœïœïœïœïœïœïœ
ïœïœïŒãã¢ãã¹ãã³ïŒããã·ãºããïŒãã¢ãã·ããããã¢ã¶ã·ããžã³ãããã»ãã ïŒã«ã«ã ã¹ãã³ïŒããã¬ãªãã¯ïŒããªãã¹ã¿ããïŒãããªãã¹ã¿ããããã³ãã ã¹ãã³å¡©é
žå¡©ããããã·ãºããããããµããã³ããããµãŒã«ïŒãã·ãã¢ããããã³ïŒ© 131ãšãŠçŽ ãã·ãã¢ããïŒããã«ã«ã¿ãããïœïŒ£ïŒ®ïŒµïŒã«ã«ã ã¹ãã³ïŒããã¬ãªãã€ã·ã³ãããªããã¢ãããããªã³ãµã€ãïŒããªããã¢ããïŒããã«ããŸããããã·ã¥ãªãïŒãã¹ãããïŒããã¹ãããããã¬ã³ããã·ãããããã³ããã¹ã«ãã¡ã³ããã¹ã«ãã§ã¯ã¹ïŒãã¹ã«ãã¡ã³ïŒãã«ããžã¿ãã»ã«ãã«ãã¶ã³ãããââãªã³ãŽé
žå¡©ãããã£ã³ãã¹ïŒã¢ã¬ã ããºããïŒãã«ã³ãããµãŒã«ïŒã€ãªããã«ã³å¡©é
žå¡©ïŒãã«ãã·ã¿ãã³ããã«ã«ããã©ãã³ãã«ã«ããã©ãã³âã¿ããœãŒã«ãã«ã«ãã£ã«ãŸãããã«ã«ã ããªã¹ïŒã«ã«ã ã¹ãã³ïŒãã«ã«ã ã¹ãã³ãã«ã«ã ã¹ãã³ã€ã³ãã©ã³ããã«ãœããã¯ã¹ïŒãã«ã«ã¿ããïŒãïœ
ïœ
ïŒãã ã¹ãã³ïŒãã»ãªããããã»ã«ããžã³ïŒããŠãã«ãã·ã³å¡©é
žå¡©ïŒããµãŒããªãã¯ã¹ïŒçµæãäºäŸ¡ã¯ã¯ãã³ïŒãã»ããã·ãããã¯ãã©ã ãã·ã«ãã¯ãã©ã ãã·ã«ïŒãã¬ãããŸã³ããã·ã¹ãã©ãã³ãã¯ã©ãã§ã³ïŒã·ã¯ããã¹ãã¡ããïŒãã¯ããã¡ã©ãã³ãïŒïŒŠãã³ã¡ããªã¯ïŒã«ãã¶ã³ãããïŒïŒ³ïŒãªã³ãŽé
žå¡©ïŒããïŒïŒ¡ïŒ¢ïŒ¶ãã³ã¹ã¡ã²ã³ïŒãã¯ãããã€ã·ã³ïŒãã¯ãªãŸãããããã·ã¯ããã¹ãã¡ããããµã€ãã©ã¹ïŒã€ãã¹ãã¡ããïŒããµã€ã©ã ã¶ïŒã©ã ã·ã«ããïŒãã·ã¿ã©ãã³ãã·ã¿ã©ãã³ããªããœãŒãã«ãã·ããµãŒã«âïŒã·ã¿ã©ãã³ïŒãã·ãããµã³ïŒã·ã¯ããã¹ãã¡ããïŒãããã©ãã§ããããã«ã«ããžã³ããã³ã²ã³ïŒãã·ã¿ãã³ïŒããã¯ãããã€ã·ã³ãããµããããããŠãã«ãã·ã³å¡©é
žå¡©ããã·ã¿ãã³ããã¬ã¬ãªã¯ã¹ããããã€ãã³ãžãããã¯ã¹ãããã¹ããããããµã€ãïŒãªããœãŒãã«ã·ã¿ã©ãã³ïŒããããã©ãŒã ïŒãªããœãŒãã«ã·ã¿ã©ãã³ïŒããã¯ã¹ã©ãŸããµã³å¡©é
žå¡©ããžãããã·ããããã»ã¿ãã»ã«ãããã·ã«ïŒãããœã«ãã·ã³å¡©é
žå¡©ãªããœãŒã ïŒããããœã«ãã·ã³å¡©é
žå¡©ããããœã«ãã·ã³å¡©é
žå¡©ãªããœãŒã ãïœïœâïŒãããœã«ãã·ã³å¡©é
žå¡©ãªããœãŒã ïŒãïŒïŒ€ïœïœïœ
ïŒãã«ã«ããžã³ïŒããšãããã¯ã¹ïŒãã«ãªããŠã©ã·ã«ïŒããšãªããã¯ïŒã©ã¹ããªã«ãŒãŒïŒããšã¬ã³ã¹ïŒãšãã«ãã·ã³å¡©é
žå¡©ïŒããšãããµãã³ïŒãªããµãªãã©ãã³ïŒããšã«ããã³ããã°ãªã©ãã³ãã€ã¡ã³ãïŒã¢ãã¬ãã¿ã³ãïŒããšã³ã¶ã«ã¿ããããšãã«ãã·ã³å¡©é
žå¡©ããã¢ãŒãã¿ãã¯ã¹ïŒã»ããã·ããïŒãã¡ã·ã«é
žãšãªããªã³ããšãªãããžïŒãã¹ã¢ãã®ãïŒããšã«ããããå¡©é
žå¡©ããšã«ãŠã£ããŒãŒïŒã¢ã¹ãã©ã®ããŒãŒãšã«ãŠã£ãã¢ã¯ãªãµã³ããïŒããšãããã¹ïŒãªã³é
žãšããã·ãïŒããšããã·ãããªã³é
žãšããã·ãããšãã»ããïŒãããœã«ãã·ã³å¡©é
žå¡©ãªããœãŒã ïŒããšãããªã ã¹ããšãã¹ã¿ïŒã©ããã·ãã§ã³å¡©é
žå¡©ïŒããšãã»ã¡ã¹ã¿ã³ããã§ã¢ã¹ãã³ïŒãã¬ããã§ã³ïŒããã¡ãªãŒããã¯ïŒããããã¹ã¿ããïŒããã¡ã¹ãããã¯ã¹ïŒãã«ãã¹ãã©ã³ãïŒãããã§ãã©ïŒã¬ãããŸãŒã«ïŒããã£ã«ã°ã©ã¹ãã ããã«ãã©ïŒãªã³é
žãã«ãã©ãã³ïŒããªã³é
žãã«ãã©ãã³ããã«ãªããã¬ãã¯ã¹ïŒãã«ãªããŠã©ã·ã«ïŒããã«ãªããŠã©ã·ã«ããã©ã¬ãã¯ã¹ïŒã¡ããã¬ããµãŒãïŒããã©ã¬ãã¯ã¹ïŒ°ïŒŠïŒ³ïŒã¡ããã¬ããµãŒãïŒããã©ã«ãã£ãªããã©ã«ãã£ãªâããã·ãºããããã©ã«ãã£ãªïŒã»ããã·ããããã©ã«ãã£ãªããã¯ã¹ããã©ã«ãããã¯ã¹ããã©ããã³ïŒãã©ã©ãã¬ããµãŒãïŒãâããã«ãã¹ãã©ã³ããã¬ãŒãã·ã«ïŒçµæãå䟡ã¯ã¯ãã³ïŒãã¬ãŒãã·ã«9ïŒçµæãä¹äŸ¡ã¯ã¯ãã³ïŒãã¬ãžãïŒãªããããºããïŒãã²ãã£ããããã²ã ã·ã¿ãã³å¡©é
žå¡©ãã²ã ã·ã¿ãã³ïŒã·ã¹ãã©ãã³ãã²ã ã·ã¿ãã³ïŒãªããµãªãã©ãã³ãã²ã ããºãããªãŸã¬ãã€ã·ã³ããžã§ã ã¶ãŒã«ïŒã²ã ã·ã¿ãã³å¡©é
žå¡©ïŒããžãªããªãïŒãžãã¬ã€ã³é
žã¢ãã¡ãããïŒãã°ãªããã¯ïŒã€ããããã¡ã·ã«é
žå¡©ïŒãã®ãªã¢ãã«ïŒã«ã«ã ã¹ãã³ã€ã³ãã©ã³ãïŒãã®ãªã¢ãã«ãŠãšããŒïŒã«ã«ã ã¹ãã³ã€ã³ãã©ã³ãïŒãã°ã«ã«ã«ãããŒãŒãé
¢é
žãŽã»ã¬ãªã³ããã©ãã³ïŒã¡ã·ã«é
žãšãªããªã³ïŒãããŒã»ããã³ïŒãã©ã¹ããºããïŒãçµæãäºäŸ¡ã¯ã¯ãã³ãçµæãä¹äŸ¡ã¯ã¯ãã³ãçµæãå䟡ã¯ã¯ãã³ããã€ã«ã ãã³ïŒå¡©é
žãããã«ã³ïŒãïœïœïœ
ïœâãã€ãã©ã³ã¹ïŒãã«ãã·ã¯ãªãïŒãã€ããªãã¢ããããŠãã»ã¿ã³ãã€ãã«ãããããã¢ã€ã¯ã«ã·ã°ïŒãããããå¡©é
žå¡©ïŒãã€ããã€ã·ã³ïŒã€ãã«ãã·ã³å¡©é
žå¡©ïŒãã€ãã«ãã·ã³å¡©é
žå¡©ãã€ãã©ãªã·ããã€ãã§ãã¯ã¹ïŒã€ãã¹ãã¡ããïŒãã€ãã¹ãã¡ãããã€ãã¹ãã¡ããã ïŒã€ãã¹ãã¡ããïŒãã¡ã·ã«é
žã€ãããããã€ã ãã«ãã«ïŒã€ãã«ãããïŒãã€ããã¢ããã€ã³ã©ã€ã¿ïŒã¢ãã·ãããïŒãã€ã³ããã³ïŒ¡ïŒçµæãã€ã³ã¿ãŒãã§ãã³Î±ïŒ2ïœïŒããšãŠçŽ 131ãã·ãã¢ããããã³ãã·ãã¢ãããã€ããªã ãããã€ã¬ããµïŒã²ãã£ãããïŒãã€ãªããã«ã³å¡©é
žå¡©ãã€ã¹ãããã¯ã¹ïŒããããã·ã³ïŒãã€ã¯ãµãããã³ãã€ã°ãŒã³ãã©ïŒã€ã¯ãµãããã³ïŒããžã£ã«ãã£ïŒãªã³é
žã«ããœãªãããïŒããžã§ãã¿ãïŒã«ããžã¿ãã»ã«ïŒãã«ããµã€ã©ïŒã¢ããã©ã¹ããºãããšã ã¿ã³ã·ã³ïŒãã±ãªãã·ãã§ã³ïŒã©ããã·ãã§ã³å¡©é
žå¡©ïŒãã±ããã³ã¹ïŒããªãã§ã«ãã³ïŒããã€ãã«ãŒãïŒãã ãããªãºããïŒãã«ã€ãããªã¹ïŒã«ã«ãã£ã«ãŸããïŒãé
¢é
žã©ã³ã¬ãªãããäºãã·ã«é
žã©ãããããã¬ããªããã€ããã¡ã·ã«é
žã¬ã³ãããããã¬ã³ããïŒã¡ã·ã«é
žã¬ã³ããããïŒãã¬ãããŸãŒã«ããã€ã³ããªã³ã«ã«ã·ãŠã ããã€ã±ã©ã³ïŒã¯ãã©ã ãã·ã«ïŒãé
¢é
žãã€ãããªããã¬ãã©ã³ïŒã¢ããã¬ããªã³é
žïŒããªã³ãã©ãªãžã³ïŒã¯ãã©ã ãã·ã«ïŒããªãããã¯ã¹ïŒãããœã«ãã·ã³å¡©é
žå¡©ãªããœãŒã ïŒããªããœãŒãã«ã·ã¿ã©ãã³ããã ã¹ãã³ãã«ããã³ïŒé
¢é
žãã€ãããªãïŒãã«ããã³ããïŒé
¢é
žãã€ãããªãïŒãã«ããã³ããïŒïŒ°ïœ
ïœïŒé
¢é
žãã€ãããªãïŒãã«ããã³ãã3ã¶æ補å€ïŒé
¢é
žãã€ãããªãïŒãã«ããã³ãã4ã¶æ補å€ïŒé
¢é
žãã€ãããªãïŒããªã ããŒã¶ïŒãªã©ããªãïŒããã«ããïŒãã³ã¯ãªã¹ãã³ç¡«é
žå¡©ãªããœãŒã ïŒãããã¥ã¬ãŒã³ïŒããã«ã«ããžã³å¡©é
žå¡©ïŒãã¡ã¯ãã¬ã¿ãã³å¡©é
žå¡©ãã¡ã²ãŒã¹ïŒé
¢é
žã¡ã²ã¹ãããŒã«ïŒãé
¢é
žã¡ã²ã¹ãããŒã«ãã¡ããã¹ãïŒãã©ã¡ãããïŒãã¡ã«ã«ããããªã³ãã¡ã¹ããã¡ã¹ããã¯ã¹ïŒã¡ã¹ãïŒãã¡ã¿ãŸã©ã¹ãã³ïŒãã¢ãŸãããïŒãã¡ããã¬ããµãŒããã¡ããã¬ããµãŒãïŒã¡ããã¬ããµãŒãïŒãã¡ããµãŒãïŒã¡ããã¬ããµãŒãïŒãã¡ããµãŒãâïŒã¡ããã¬ããµãŒãïŒããã€ããã€ã·ã³ïŒ£ãããããµã³ããã³å¡©é
žå¡©ãããã¶ã€ãã¬ãã¯ã¹ïŒãã€ããã€ã·ã³ïŒ£ïŒãïŒïŒ¯ïŒ°ïŒ°ãã¢ãŸãã«ïŒãã¬ãªããµãã©ã«ïŒãã ã¹ã¿ã«ã²ã³ïŒã¡ã¯ãã¬ã¿ãã³å¡©é
žå¡©ïŒãã ã¿ãã€ã·ã³ïŒãã€ããã€ã·ã³ïŒ£ïŒããã¬ã©ã³ïŒãã¹ã«ãã¡ã³ïŒããã€ããµãŒã«ïŒã¢ã¶ã·ããžã³ïŒããã€ãã¿ãŒã°ïŒã²ã ããºãããªãŸã¬ãã€ã·ã³ïŒãããç²åãã¯ãªã¿ãã»ã«ïŒãã¯ãªã¿ãã»ã«ã»ã¢ã«ããã³å®å®åããç²å補å€ïŒãããã«ãã³ïŒããã¬ã«ãã³é
ç³é
žå¡©ïŒããã©ã©ãã³ãããªãµãŒã«ïŒã·ã¯ããã¹ãã¡ããïŒããããã¿ã³ãããã³ãããã»ããã³å¡©é
žå¡©ããã¥ãŒããžã§ã³ïŒãã£ã«ã°ã©ã¹ãã ïŒããã¯ãµããŒã«ïŒãœã©ãã§ãããã·ã«é
žå¡©ïŒãããããããããã«ããããã«ãããã¯ã¹ïŒã¿ã¢ãã·ãã§ã³ã¯ãšã³é
žå¡©ïŒããã¬ãŒãïŒããããã¹ãã ïŒããªããããºãããããªãã¡ãã ãããããªã©ããªãããªãã»ã¿ãã·ã³ã¡ããµã¯ã·ããŒãããªã³ãã£ã¹ããŒïŒãã°ã¢ã¹ãã«ã¬ãŒãŒïŒããªã³ã¿ãã¯ïŒãããã€ãã³ãžãããã¯ã¹ïŒããªããžãŒãïŒããã«ããïŒãããªããµãªãã©ãã³ããã¯ãªã¿ãã»ã«ããã¯ãªã¿ãã»ã«ã»ã¢ã«ããã³å®å®åããç²å補å€ãããã«ãã·ã¯ãªããããªãã§ã«ãã³ããããã»ããã³å¡©é
žå¡©ãããããã³é
žäºãããªãŠã ããããã ãããããããã¹ã¿ããããã©ãã©ããïŒã«ã«ããã©ãã³ïŒããã©ãã©ãã³ïŒã«ã«ããã©ãã³ïŒãããŸãããå¡©é
žå¡©ããã°ã¢ã¹ãã«ã¬ãŒãŒããã°ã€ã³ã¿ãŒãã§ãã³Î±â2ïœãâã€ã³ããã³ïŒãã°ã€ã³ã¿ãŒãã§ãã³Î±â2ïœïŒããã ãããªãºããããã¡ãã¬ãã»ãäºãããªãŠã ãããŒãžã§ã¿ïŒãã«ããºããïŒããã«ããºããããã©ãããŒã«ïŒã·ã¹ãã©ãã³ïŒããã©ãããŒã«âïŒã·ã¹ãã©ãã³ïŒããã¬ãªããµãã©ã«ããããªãããããããªã¹ãïŒãããªãããïŒããããããå¡©é
žå¡©ããã©ã©ãã¬ããµãŒãããã¬ãããŸã³ãããã«ã«ããžã³å¡©é
žå¡©ããããã€ãã³ïŒã¢ã«ãã¹ãã€ãã³ïŒããããªã¢ïŒããã¹ããïŒããããã¯ã¿ïŒãšã«ããã³ããã°ãªã©ãã³ïŒããããã³ãžïŒã·ããã€ã»ã«ïŒŽïŒãããªãããŒã«ïŒã¡ã«ã«ããããªã³ïŒãããªããµã³ïŒã¡ã«ã«ããããªã³ïŒãäºå¡©åã©ãžãŠã 223ãã©ããã·ãã§ã³å¡©é
žå¡©ãã©ã ã·ã«ãããã©ã¹ããªã«ãŒãŒãâãâãçµæãããããããŒããŠã€ã«ã¹ïŒïŒšïŒ°ïŒ¶ïŒäºäŸ¡ã¯ã¯ãã³ãçµæãããããããŒããŠã€ã«ã¹ïŒïŒšïŒ°ïŒ¶ïŒä¹äŸ¡ã¯ã¯ãã³ãçµæãããããããŒããŠã€ã«ã¹ïŒïŒšïŒ°ïŒ¶ïŒå䟡ã¯ã¯ãã³ãçµæãã€ã³ã¿ãŒãã§ãã³Î±â2ïœãã¬ãŽã©ãã§ãããâãã¬ããªããïŒã¬ããªãããïŒããªãŠããã¬ãã¯ã¹ïŒã¡ããã¬ããµãŒãïŒããªãããµã³ïŒãªããã·ããïŒããªããã·ãããããããã·ã³ãããããã¹ãã ãã«ãããã€ã·ã³ïŒããŠãã«ãã·ã³å¡©é
žå¡©ïŒãã«ããœãªããããªã³é
žå¡©ãã¹ã¯ã¬ããŸãŒã«èžèå
ãšã¢ããŸã«ïŒã¿ã«ã¯ïŒãã·ã«ããã·ãããã·ããã€ã»ã«ïŒŽããœããã¥ãªã³ããïŒã©ã³ã¬ãªããé
¢é
žå¡©ïŒããœã©ãã§ãããã·ã«é
žå¡©ãã¹ããªã»ã«ïŒããµãããïŒãã¹ã¿ã³ãã©ãŒããæ»
èã¿ã«ã¯ç²æ«ïŒã¿ã«ã¯ïŒãã¹ããªã¿ã«ã¯ïŒã¿ã«ã¯ïŒãã¹ãããŒã¬ïŒã¬ãŽã©ãã§ããïŒãã¹ãããããªã³ãŽé
žå¡©ãã¹ãŒãã³ãïŒã¹ãããããªã³ãŽé
žå¡©ïŒãã·ã©ããã³ïŒãã°ã€ã³ã¿ãŒãã§ãã³Î±â2ïœïŒãã·ã«ãã³ãïŒã·ã«ããã·ããïŒãã·ãããŒã«ïŒãµãªããã€ãïŒãã·ã³ãªãïŒãªãã»ã¿ãã·ã³ã¡ããµã¯ã·ããŒãïŒããã¿ãã£ã³ã©ãŒïŒããã©ãã§ããïŒãã¿ã«ã¯ãã¿ã¢ãã·ãã§ã³ã¯ãšã³é
žå¡©ãã¿ã©ãã³ïŒ°ïŒŠïŒ³ïŒã·ã¿ã©ãã³ïŒãã¿ã«ã»ãïŒãšã«ããããå¡©é
žå¡©ïŒãã¿ã«ã°ã¬ãã³ïŒãããµããã³ïŒãã¿ã·ã°ãïŒãããããïŒãã¿ããœãŒã«ïŒãã¯ãªã¿ãã»ã«ïŒãã¿ããœããŒã«ïŒãã»ã¿ãã»ã«ïŒããã¢ããŒã«ïŒãã¢ãŸãããïŒããã¢ãŸãããããã ã·ããªã ã¹ããµãªããã€ãããµãããïŒãµãªããã€ãïŒãããªããããããµãŒã«ïŒãšããã·ãïŒããããã«ã³å¡©é
žå¡©ããã¬ããã§ã³ãããŒãªã»ã«ïŒãã ã·ããªã ã¹ïŒããã·ãã¢ããããã³ïŒ©131ãšãŠçŽ ãã·ãã¢ãããããã¯ãïŒãã¯ã¹ã©ãŸããµã³å¡©é
žå¡©ïŒãããã©ã¡ãããããã©ã¹ããºããããã¬ã¢ã³ãïŒãã³ãã ã¹ãã³å¡©é
žå¡©ïŒãããªã»ããã¯ã¹ïŒäžé
žåãçŽ ïŒãã¿ã€ã±ã«ãïŒäºãã·ã«é
žã©ããããïŒããŠãããã·ã³ïŒãžãããã·ããïŒããã³ãã¿ãããïŒïŒ°ããã¯ãããã¯ã¹ïŒãããã ããïŒãïœ
ããã«ãã³ïŒãã³ãã©ã¹ãã³ç¡«é
žå¡©ïŒããã«ã±ã€ãïŒãã«ããŸããïŒããã«ãµãŒã«ïŒãã³ãã©ã¹ãã³ç¡«é
žå¡©ïŒããã ã©ãã§ãããããã·ãïŒãšããã·ãïŒããã¢ãã¥ãŒã«ïŒé
¢é
žãã€ãããªãïŒããããŒã¶ïŒã¢ã¶ã·ããžã³ïŒããã³ãã©ã¹ãã³ç¡«é
žå¡©ããã³ã«ãµãŒã«ïŒ°ïŒŠïŒ³ïŒãã³ã¯ãªã¹ãã³ãµã«ãã§ãŒãïŒããã³ã¯ãªã¹ãã³ç¡«é
žå¡©ããã³ã¯ãªã¹ãã³ç¡«é
ž
å¡©ãªããœãŒã ãããã¬ã«ãã³é
ç³é
žå¡©ãããã¹ã¢ãã®ãããã©ã¯ãµãŒãŒïŒã°ã«ã«ã«ãããŒãŒïŒãããªãã¹ã¿ããããŽã©ããªãšã³ãïŒããŸãããå¡©é
žå¡©ïŒããŠã§ã«ã³ããªã³ïŒãã€ã³ããªã³ã«ã«ã·ãŠã ïŒãã¶ãŒã³ãªïŒã¯ãªãŸãããïŒããŒããŒãïŒã«ãã·ã¿ãã³ïŒããããšã¯ã¹ãžãïŒããã¹ããïŒããŸãŒãã£ãŽïŒäºå¡©åã©ãžãŠã 223ïŒãã€ã¯ã¹ã¿ã³ãžïŒãšã³ã¶ã«ã¿ããïŒãã€ãŒãã€ïŒã€ããªã ããïŒãã¶ã«ãã©ããïŒïŒºïœïœâã¢ããªãã«ã»ããïŒããŒã«ãã©ãïŒãã ã©ãã§ããïŒããŒãŽã¡ãªã³ïŒã€ããªãã¢ããããŠãã»ã¿ã³ïŒãã¶ã€ã³ã«ãŒãïŒãã¯ã¹ã©ãŸããµã³å¡©é
žå¡©ïŒãïœïœâã¢ããªãã«ã»ããããŸã©ããã¯ã¹ïŒé
¢é
žãŽã»ã¬ãªã³ïŒããŸã¬ããã³é
žããŸãªã³ã¶ïŒããªãã¹ã¿ããïŒããŸã¡ã¿ïŒãŸã¬ããã³é
žïŒãã¶ã€ããªã°ïŒã€ãã©ãªã·ãïŒããžã«ãã£ã¢ïŒã»ãªãããïŒããŸãã¯ã¶ã€ãã£ã¬ïŒé
¢é
žã¢ãã©ããã³ïŒã§ãããæ¬çºæ1030ã®æ¹æ³ã
[æ¬çºæ1032]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ã察象ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããŠè
«ç现èãé»å®³ãŸãã¯äœæžããæ¹æ³ã
[æ¬çºæ1033]
åèšè
«ç现èã®æ°ãã察ç
§å€ãŸãã¯åç
§å€ãšæ¯èŒããŠãå°ãªããšãçŽ10ïŒ
ãå°ãªããšãçŽ20ïŒ
ãå°ãªããšãçŽ30ïŒ
ãå°ãªããšãçŽ40ïŒ
ãå°ãªããšãçŽ50ïŒ
ãå°ãªããšãçŽ60ïŒ
ãå°ãªããšãçŽ70ïŒ
ãå°ãªããšãçŽ80ïŒ
ãå°ãªããšãçŽ90ïŒ
ããŸãã¯å°ãªããšãçŽ100ïŒ
æžå°ãããæ¬çºæ1032ã®æ¹æ³ã
[æ¬çºæ1034]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ã察象ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããŠïŒ£ïŒ€3ãçºçŸãã现èã«ãããµã€ãã«ã€ã³ã®ç£çãå¢å ãããæ¹æ³ã
[æ¬çºæ1035]
现èããæ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ãšæ¥è§Šãããããšãå«ããåèšïŒŽçŽ°èã«ãããïŒ2ã69ãããã³ïŒãŸãã¯ïŒ©ïŒŠïŒ®ïŒÎ³ã®ç£çãŸãã¯æ¿åºŠãå¢å ãããæ¹æ³ã
[æ¬çºæ1036]
ïŒÎ³ç£çãã察ç
§å€ãŸãã¯åç
§å€ãšæ¯èŒããŠãå°ãªããšãçŽ100ïŒ
ãå°ãªããšãçŽ200ïŒ
ãå°ãªããšãçŽ300ïŒ
ãå°ãªããšãçŽ400ïŒ
ãå°ãªããšãçŽ500ïŒ
ãå°ãªããšãçŽ600ïŒ
ãå°ãªããšãçŽ700ïŒ
ãå°ãªããšãçŽ800ïŒ
ãå°ãªããšãçŽ900ïŒ
ããŸãã¯å°ãªããšãçŽ1000ïŒ
å¢å ãããæ¬çºæ1035ã®æ¹æ³ã
[æ¬çºæ1037]
ïŒÎ³æ¿åºŠãã察ç
§å€ãŸãã¯åç
§å€ãšæ¯èŒããŠãå°ãªããšãçŽ1000ïœïœïŒïœïœãå°ãªããšãçŽ2000ïœïœïŒïœïœãå°ãªããšãçŽ3000ïœïœïŒïœïœãå°ãªããšãçŽ4000ïœïœïŒïœïœãå°ãªããšãçŽ5000ïœïœïŒïœïœãå°ãªããšãçŽ6000ïœïœïŒïœïœãå°ãªããšãçŽ7000ïœïœïŒïœïœãå°ãªããšãçŽ8000ïœïœïŒïœïœãå°ãªããšãçŽ9000ïœïœïŒïœïœããŸãã¯å°ãªããšãçŽ10000ïœïœïŒïœïœå¢å ãããæ¬çºæ1035ã®æ¹æ³ã
[æ¬çºæ1038]
69ç£çãã察ç
§å€ãŸãã¯åç
§å€ãšæ¯èŒããŠãå°ãªããšãçŽ1ïŒ
ãå°ãªããšãçŽ2ïŒ
ãå°ãªããšãçŽ3ïŒ
ãå°ãªããšãçŽ4ïŒ
ãå°ãªããšãçŽ5ïŒ
ãå°ãªããšãçŽ6ïŒ
ãå°ãªããšãçŽ7ïŒ
ãå°ãªããšãçŽ8ïŒ
ãå°ãªããšãçŽ9ïŒ
ãå°ãªããšãçŽ10ïŒ
ãå°ãªããšãçŽ15ïŒ
ãå°ãªããšãçŽ20ïŒ
ãå°ãªããšãçŽ25ïŒ
ããŸãã¯å°ãªããšãçŽ30ïŒ
å¢å ãããæ¬çºæ1035ã®æ¹æ³ã
[æ¬çºæ1039]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ã察象ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããå
ç«å¿çãåºæ¿ããæ¹æ³ã
[æ¬çºæ1040]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ã察象ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããç现èã«å¯Ÿãã现èåªä»æ§çŽ°èå·å®³æ§å
ç«å¿çãåºæ¿ããæ¹æ³ã
[æ¬çºæ1041]
现èããæ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ãšæ¥è§Šãããããšãå«ãã现èå¢æ®ãå¢å ãããæ¹æ³ã
[æ¬çºæ1042]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ã察象ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã®è
«çã«ãããå¶åŸ¡æ§ïŒŽçŽ°èã®æ°ãæžå°ãŸãã¯æ¯æžãããæ¹æ³ã
[æ¬çºæ1043]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã䜿çšããŠã察象ã®è©Šæäžã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã決å®ããããšãå«ããåèšå¯Ÿè±¡ã«ãããçãŸãã¯ç転移ã®äºæž¬ã蚺æããŸãã¯äºåŸå€å®ã®ããã®æ¹æ³ã
[æ¬çºæ1044]
ïŒïœïŒæ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã䜿çšããŠã察象ã®è©Šæäžã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã決å®ãŸãã¯å®éåããããšãããã³ïŒïœïœïŒå·¥çšïŒïœïŒã§åŸãããåèšçºçŸã¬ãã«ã察ç
§å€ãŸãã¯åç
§å€ãšæ¯èŒããããšãå«ã¿ãããã§ãåèšå¯Ÿç
§å€ãŸãã¯åç
§å€ã«å¯ŸããïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã®å¢å ããçãçãçºçããé«ããªã¹ã¯ããŸãã¯çã®äºåŸäžè¯ã瀺ããæ¬çºæ1043ã®æ¹æ³ã
[æ¬çºæ1045]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã䜿çšããŠã察象ã®è©Šæäžã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã決å®ããããšãå«ããåèšå¯Ÿè±¡ã«ãããè
«çé²è¡ãŸãã¯è
«ç浞最æ§ã®äºæž¬ã蚺æããŸãã¯äºåŸå€å®ã®ããã®æ¹æ³ã
[æ¬çºæ1046]
ïŒïœïŒæ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã䜿çšããŠã察象ã®è©Šæäžã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã決å®ãŸãã¯å®éåããããšãããã³ïŒïœïœïŒå·¥çšïŒïœïŒã§åŸãããåèšçºçŸã¬ãã«ã察ç
§å€ãŸãã¯åç
§å€ãšæ¯èŒããããšãå«ã¿ãããã§ãåèšå¯Ÿç
§å€ãŸãã¯åç
§å€ã«å¯ŸããïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã®å¢å ããè
«çé²è¡ãŸãã¯è
«ç浞最æ§ã®äºåŸäžè¯ã瀺ããæ¬çºæ1045ã®æ¹æ³ã
[æ¬çºæ1047]
以äžã®å·¥çšïŒ
åèšè©Šæäžã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ãå®éåããããã«å®éšå®€ã«æ瀺ããããšïŒ
å®éšå®€ããåèšè©Šæäžã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã®å ±åãåŸãããšïŒããã³ïŒãŸãã¯
æ²»çæå¹éã®ïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®é»å®³å€ãåèšå¯Ÿè±¡ã«æäžããããš
ã®1ã€ä»¥äžãããã«å«ããæ¬çºæ1043ïœ1046ã®ããããã®æ¹æ³ã
[æ¬çºæ1048]
åèšè©Šæããåèšå¯Ÿè±¡ããã®çµç¹çæ€ãè
«ççæ€ããŸãã¯è¡æ¶²è©Šæã§ãããæ¬çºæ1043ïœ1047ã®ããããã®æ¹æ³ã
[æ¬çºæ1049]
åèšå¯Ÿç
§å€ãŸãã¯åç
§å€ããæ£åžžçµç¹ãŸãã¯æ£åžžé£æ¥çµç¹ïŒïŒ®ïŒ¡ïŒŽïŒã«ãããïŒïŒ¯ïŒ³ïŒ°ïŒ€2ã®çºçŸã¬ãã«ã§ãããæ¬çºæ1043ïœ1048ã®ããããã®æ¹æ³ã
[æ¬çºæ1050]
åèšå¯Ÿç
§å€ãŸãã¯åç
§å€ããæ€åºå¯èœãªïŒïŒ¯ïŒ³ïŒ°ïŒ€2çºçŸããªããããŸãã¯ææãªïŒïŒ¯ïŒ³ïŒ°ïŒ€2çºçŸããªãããšã§ãããæ¬çºæ1043ïœ1048ã®ããããã®æ¹æ³ã
[æ¬çºæ1051]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ããïŒïŒ¯ïŒ³ïŒ°ïŒ€2çºçŸè
«çãæ²»çãŸãã¯äºé²ããã®ã«æå¹ãªéã§å¯Ÿè±¡ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããïŒïŒ¯ïŒ³ïŒ°ïŒ€2çºçŸè
«çãæ²»çãŸãã¯äºé²ããæ¹æ³ã
[æ¬çºæ1052]
æ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ããïŒïŒ¯ïŒ³ïŒ°ïŒ€2çºçŸè
«çé¢é£ãã¯ããã¡ãŒãžãæããè
«çãæ²»çãŸãã¯äºé²ããã®ã«æå¹ãªéã§å¯Ÿè±¡ã«æäžããããšãå«ããåèšå¯Ÿè±¡ã«ãããïŒïŒ¯ïŒ³ïŒ°ïŒ€2çºçŸè
«çé¢é£ãã¯ããã¡ãŒãžãæããè
«çãæ²»çãŸãã¯äºé²ããæ¹æ³ã
[æ¬çºæ1053]
ïŒïœïŒæ¬çºæ1001ïœ1017ã®ããããã®äºéç¹ç°æ§æäœãããã¯ãã®æåçµåæçãŸãã¯æ¬çºæ1018ïœ1027ã®ããããã®å»è¬çµæç©ãããã³ïŒïœïœïŒäœ¿çšèª¬ææžãå«ããããã
In some embodiments, the invention comprises (i) a bispecific antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition described herein, and (ii) instructions for use. Regarding the kit.
[Invention 1001]
A bispecific antibody or antigen-binding fragment thereof comprising (i) one or more antigen-binding domains for MOSPD2 and (ii) one or more antigen-binding domains for T cell or NK cell-specific receptor molecules.
[Invention 1002]
The dual of the invention 1001 wherein the T cell or NK cell specific receptor molecule is CD3, T cell receptor (TCR), CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, or CD95. Specific antibody or antigen-binding fragment thereof.
[Invention 1003]
The one or more antigen-binding domains for MOSPD2 are Fab, Fab', F (ab') 2 , Fv, scFv, sdFv fragments, heavy chain variable regions, light chain variable regions, etc. of anti-MOSPD2 antibodies or antigen-binding fragments thereof. Bispecific antibody of the invention 1001 or 1002 or antigen binding thereof, which is a complementarity determining region (CDR), heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2, or light chain CDR3. piece.
[Invention 1004]
The T cell or NK cell-specific receptor molecule is CD3, and one or more antigen-binding domains for CD3 are Fab, Fab', F (ab') 2 , Fv of an anti-CD3 antibody or an antigen-binding fragment thereof. , ScFv, sdFv fragment, heavy chain variable region, light chain variable region, CDR, heavy chain CDR1, heavy chain CDR2, heavy chain CDR3, light chain CDR1, light chain CDR2, or light chain CDR3, the present invention 1001-1003. Any of the bispecific antibodies or antigen-binding fragments thereof.
[Invention 1005]
The following antigen-binding domains:
(I) Heavy chain variable region of anti-MOSPD2 antibody or antigen-binding fragment thereof; and
(Ii) Light chain variable region of anti-MOSPD2 antibody or antigen-binding fragment thereof
A bispecific antibody or antigen-binding fragment thereof according to any of 1001 to 1004 of the present invention, which comprises one or more of the above.
[Invention 1006]
The following antigen-binding domains:
(I) Heavy chain variable region of anti-CD3 antibody or antigen-binding fragment thereof; and
(Ii) Light chain variable region of anti-CD3 antibody or antigen-binding fragment thereof
A bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1005, which comprises one or more of the above.
[Invention 1007]
The following antigen-binding domains:
(I) Heavy chain variable region of anti-MOSPD2 antibody or antigen-binding fragment thereof;
(Ii) Light chain variable region of anti-MOSPD2 antibody or antigen-binding fragment thereof;
(Iii) Heavy chain variable region of anti-CD3 antibody or antigen-binding fragment thereof; and
(Iv) Light chain variable region of anti-CD3 antibody or antigen-binding fragment thereof
A bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1006.
[Invention 1008]
A bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1007, wherein one or more of the antigen-binding domains are linked by a peptide linker.
[Invention 1009]
A bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1008, wherein at least one antigen-binding domain is human.
[Invention 1010]
A bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1008, wherein at least one antigen-binding domain is humanized.
[Invention 1011]
The bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1010, wherein the bispecific antibody or antigen-binding fragment thereof is a single-stranded polypeptide.
[Invention 1012]
The bispecific antibody or antigen-binding fragment thereof according to any one of the present inventions 1001 to 1011, wherein the bispecific antibody or antigen-binding fragment thereof has a molecular weight of about 60,000 Dalton or less.
[Invention 1013]
Bispecific antibodies include Nanobodies, Diabodies, Duobodies, CrossMabs, bivalent antibodies, bispecific T cell engagers (BiTE), dual affinity retargeting (DART), triple bodies, mini-antibodies. A bispecific antibody or antigen-binding fragment thereof from any of the present inventions 1001 to 1012, which is a TriBi minibody, intrabody, or quadroma.
[Invention 1014]
The invention 1001-1013 , wherein the bispecific antibody or antigen-binding fragment thereof specifically binds to MOSPD2 and / or CD3 with an equilibrium dissociation constant ( KD) of about 10-6 M to about 10-12 M. Any bispecific antibody or antigen-binding fragment thereof.
[Invention 1015]
INDUSTRIAL APPLICABILITY: The bispecific antibody or antigen-binding fragment, or one or more antigen-binding domains to MOSPD2 specifically bind to one or more of SEQ ID NOs: 1-4 or functional variants thereof. Any of 1014 bispecific antibodies or antigen-binding fragments thereof.
[Invention 1016]
The bispecific antibody or antigen binding fragment, or one or more antigen binding domains to MOSPD2, specifically bind to one or more of SEQ ID NOs: 5-8, or a polypeptide encoded by a functional variant thereof. The bispecific antibody of the present invention 1001 to 1015 or an antigen-binding fragment thereof.
[Invention 1017]
The bispecific antibody or antigen-binding fragment, or one or more antigen-binding domains to MOSPD2, specifically bind to MOSPD2 at a KD of about 10-6 M to about 10-12 M, 1001 to 1001 of the present invention . Any of 1016 bispecific antibodies or antigen-binding fragments thereof.
[Invention 1018]
A pharmaceutical composition comprising any bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof, and a pharmaceutically acceptable carrier.
[Invention 1019]
The pharmaceutical composition of the present invention 1018 suitable for systemic administration.
[Invention 1020]
The pharmaceutical composition of the present invention 1018 suitable for local administration.
[Invention 1021]
The pharmaceutical composition of the present invention 1018 suitable for oral administration.
[Invention 1022]
The pharmaceutical composition of the present invention 1018 suitable for nasal administration.
[Invention 1023]
The pharmaceutical composition of the present invention 1018 suitable for intraperitoneal administration.
[Invention 1024]
The pharmaceutical composition of the present invention 1018 suitable for intratumoral administration.
[Invention 1025]
The pharmaceutical composition of the present invention 1018 suitable for intravenous administration.
[Invention 1026]
The pharmaceutical composition of the present invention 1018 suitable for intramuscular administration.
[Invention 1027]
The pharmaceutical composition of the present invention 1018 suitable for subcutaneous administration.
[Invention 1028]
The bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018 to 1027 is administered to a subject in an amount effective for treating or preventing cancer. A method of treating or preventing cancer in the subject, including the above.
[Invention 1029]
The bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the present inventions 1018 to 1027 is administered to a subject in an amount effective for treating or preventing cancer metastasis. A method of treating or preventing cancer metastasis in the subject, comprising:
[Invention 1030]
The method of the invention 1028 or 1029, further comprising administering to the subject an effective amount of an anti-cancer agent.
[Invention 1031]
The anticancer agents include avilateron acetate, abitrexate (methotrexate), abraxane (pacrytaxel albumin-stabilized nanoparticles preparation), ABVD, ABVE, ABVE-PC, AC, AC-T, ADCETRIS (brentuximabbedothin), ADE. , Adtras tsuzumabuemtancin, adriamycin (doxorubicin hydrochloride), adorsyl (fluorouracil), afatinib dimaleate, affinitol (everolims), akinzeo (netupitant and paronosetron hydrochloride), aldara (imikimod) ), Aroxy (paronocetron hydrochloride), ambochlorin (chlorambucil), amboclorin (chlorambucil), aminolevulinic acid, anastrozole, aprepitant, aredia (disodium pamidronate), arimidex (anastrozole), aromasin. (Exemestane), Alanon (Nerarabin), Arsenic trioxide, Azera (Ofatumumab), Asparaginase Erwinia chlorambucil, Avastin (Bevasizumab), Avastin (Bevasizumab), Axitinib, Azasitinib , Verinostat, Bendamstine Hydrochloride, BEP, Bebasizumab, Bexarotene, Bexal (Toshitsumomab and I 131 Iodine Toshitsumomab), Bicartamide, BiCNU (Carmustine), Breomycin, Brinatsumomab, Brynsite (Brinatumobismab), Bortezomib Tuximabubedotin, Busulfan, Busulfex (Busulfan), Cabaditaxel, Cabozantinib-S-apple salt, CAF, Campus (Alemtuzumab), Camptosar (Irinotecan hydrochloride), Capesitabin, CAPOX, Carboplatin, Carmustine-Taxol, Carmustine (Carmustine), Carmustine, Carmustine Implant, Casodex (Vicartamide), CeeNU (Romustine), Seritinib, Servisin (Doxorubicin Hydrochloride), Servisx (Recombinant HPV Bivalent Vaccine), Setuximab, Chlorambucil, Chlorambucil Mubusyl-predonison, CHOP, cisplatin, clafen (cyclophosphamide), fludarabine, CMF, cometric (cabozanthinib-S-apple salt), COPP, COPP-ABV, cosmegen (doxorubicin), crizotinib, CVP, cyclophos Famide, Cyphos (Iphosphamide), Cyramza (Ramsilmab), Citarabin, Citarabin, Liposomal, Citosar-U (Citarabin), Citoxan (Cyclophosphamide), Dabrafenib, Dacarbazine, Dacogen (decitabin), Doxorubicin, Doxorubicin Hydrochloride, decitabin, degarelix, deniroykin diphtytox, denosmab, deposite (liposomarcitarabin), depoform (liposomarcitarabin), dexrazoxane hydrochloride, dinutuximab, dosetaxel, doxil (doxorubicin hydrochloride liposome), doxorubicin hydrochloride Hydrochloride, doxorubicin hydrochloride liposomes, Dox-SL (doxorubicin hydrochloride liposomes), DTIC-Dome (dacarbazine), efdex (fluorouracil), erytec (lasbricase), elence (epirubicin hydrochloride), eroxatin (oxaliplatin), el Thrombopaguolamine, Imend (Aprepitant), Enzartamide, Epirubicin Hydrochloride, EPOCH, Arbitax (Setuximab), Elibrine Mesylate, Erivedge (Bismodegib), Elrotinib Hydrochloride, Elwinase (Asparaginase Elwinia Chrysantemi), Etopophosphamide Etoposide), Etoposide, Phosphate Etoposide, Evaset (doxorubicin hydrochloride liposome), Eberolimus, Evista (laroxyphene hydrochloride), Exemestane, Fairston (Tremiphen), Faridadack (Panobinostat), Faslodex (Fullbestland), FEC , Femara (Retrozole), Philgrastim, Fludarabine (Fludarabine Phosphate), Fludarabine Phosphate, Fluoroplex (Fluorouracil), Fluorouracil, Forex (Mettrexate), Forex PFS (Mettrexate), Forfili, Forfili-bebasiszumab, Forfili-setuximab , Forfilinox, Forflox, Forotin (Plaratrexate), FU-LV, Fludarabine, Gardacil (Recombinant HPV) (Four-valent vaccine), Gardacil 9 (recombinant HPV nine-valent vaccine), Gaziba (obinutuzumab), gemcitabine, gemcitabine hydrochloride, gemcitabine-cisplatin, gemcitabine-oxaliplatin, gemcitabine ozogamicin, gemzar (gemcitabine hydrochloride) , Geotrif (Afatinib dimaleate), Gleevec (Imatinibmesilate), Giliadel (Carmustin Implant), Giliadel Wafer (Carmustin Implant), Glucalpidase, Goseleline Acetate, Haraben (Elibrin Mesylate), Herceptin (Trastuzumab), Gem Alternate HPV bivalent vaccine, recombinant HPV nine-valent vaccine, recombinant HPV tetravalent vaccine, Hycamtin (topotecan hydrochloride), Hyper-CVAD, Ibrance (palbocyclib), Ibritzumombyuxetan, ibrutinib, ICE, Iclusig (ponatinib hydrochloride) ), Idamycin (idalbisin hydrochloride), idarubicin hydrochloride, ideralisib, ifex (iphosphamide), ifofamide, ifosfamidem (iphosphamide), imatinib mesylate, imbulbica (ibrutinib), imikimod, inwriter (axitinib), inwriter (axitinib) -2b), Iodine 131 toshitumomab and toshitsumomab, ipilimumab, iressa (gefitinib), irinotecan hydrochloride, istodax (lomidepsin), ixavepyrone, igzenpra (ixabepirone), jakafi (luxabepyrone) Emtancin), Keoxyphen (Laloxyphene Hydrochloride), Kepivans (Parifermin), Keytruda (Pembrolizumab), Kaiprolis (Carfilzomib), Lanleothide acetate, Lapatinib ditosylate, Lenalidemide, Lembatinib mesylate, Lembima (Lemcitabine mesylate) , Leucovorin calcium, leukelan (chlorambusyl), leuprolide acetate, leblanc (aminolevulinic acid), phosphoridine (chlorambusyl), lipodox (doxorbisin hydrochloride liposome), liposomarcitarabin, romstin, rupron (leuprolide acetate), ruprondepo (leuprolide acetate) Luprondepo-Ped (leuprolide acetate), Luprondepo 3-month formulation (leupronide acetate), Luprondepo 4-month formulation (acetate) Leuprolide), Lynparza (Olaparib), Marquibo (Vincristin sulfate liposome), Maturene (Procarbazine hydrochloride), Mechlormethine hydrochloride, Megeth (Megestrolexate), Megestrol acetate, Mekinist (Trametinib), Mercaptopurine, Mesna, Mesnex (Mesna), Metazolaston (Temozolomid), Methotrexate, Methotrexate LPF (Methotrexate), Mexate (Methtrexate), Mexate-AQ (Mettrexate), Mitomycin C, Mitoxanthron hydrochloride, Mitozytrex (Mitomycin C), MOPP, Mozovir (Plerixafor), Mustalgen (Methotrexate), Mutamycin (Mitomycin C), Milleran (Busulfan), Myrosal (Azacitidine), Myrotarg (Gemtuzumab ozogamycin), Nanoparticles Paclitaxel (Pacritaxel albumin stabilization) Nanoparticle formulation), navelvin (binormethine tartrate), nerarabin, neosar (cyclophosphamide), netupitant and paronosetron hydrochloride, nupogen (filgrastim), nexavar (solafenibutosylate), nirotinib, nibolumab, nolvadex (tamoxyphene) Citrate), N-plate (Lomiprostim), Obinutsumab, OEPA, Ofatumumab, OFF, Olaparib, Omasetaxin Methotrexate, Oncasper (Peguspargase), Ontac (Deniroykin difchitox), Opdivo (Nivormab), OPPA, oxaliplatin, paclitaxel, paclitaxel / albumin-stabilized nanoparticle formulation, PAD, parvocyclib, parifermin, paronosetron hydrochloride, disodium pamidronate, panitummab, panobinostat, paraplat (carboplatin), paraplatin (carboplatin), pazopanib hydrochloride , Pegua spargase, peginterferon α-2b, PEG-intron (peginterferon α-2b), pembrolizumab, pemethrexed disodium, perjeta (pelzzumab), perzzumab, platinol (cisplatin), plerixafor , Pomalidemid, Pomalist (Pomalydomido), Ponatinib hydrochloride, Pleraxate, Plermethine, Procarbazine hydrochloride, Proleukin (Al) Desroykin), Prolia (Denosumab), Promacta (Eltronbopaguolamine), Provenge (Ciploisel T), Prinetor (Mercaptopurine), Prixane (Mercaptopurine), Radium dichloride 223, Laroxyphen hydrochloride, Ramsylmab, Lasbricase, R- CHOP, R-CVP, recombinant human papillomavirus (HPV) bivalent vaccine, recombinant human papillomavirus (HPV) nine-valent vaccine, recombinant human papillomavirus (HPV) tetravalent vaccine, recombinant interferon α-2b, regorafenib, R- EPOCH, revrimid (renalidemid), rheumatrex (methotrexate), rituximab (rituximab), rituximab, lomidepsin, lomiprostim, rubidomycin (daunorbisin hydrochloride), luxolitinibphosphate, screlosyl thoracic aerosol (talxyloximab) Somatuline depot (lanleotide acetate), sorafenib tosilate, spritel (dasatinib), Stanford V, sterile talc powder (talc), steritarc (talc), stiberga (legoraphenib), sunitinib linate, sutent (sunitinib linate) ), Silatron (Peginterferon α-2b), Sylvanto (Siltuximab), Sinobeal (Salidomid), Synribo (Omasetaxin mepesuccinate), TAC, Tafinlar (Dabrafenib), Tarku, Tamoxyphencitrate, Tarabin PFS (Citarabin) , Tarceva (erlotinib hydrochloride), targretin (bexarotene), tasigna (sunitinib), taxol (pacritaxel), taxotere (docetaxel), temodar (temozolomid), temozolomid, temsirolimus, salidomid , Topotecan Hydrochloride, Tremiphen, Torisel (Temcilolimus), Toshitumomab and I131 Iodine Toshitsumomab, Totect (Dexrazoxane Hydrochloride), TPF, Tramethinib, Trastuzumab, Treanda (Bendamstin Hydrochloride), Trisenox (Hydetrioxide), Tykelb Acid Lapatinib), Unituxin (Zinutuximab), Bandetanib, VAMP, Vectibix (Panitumumab), VeIP, Velvan (Bimblastin Sulfate), Velcade (Voltezomib), Berser Lu (vinblastine sulphate), bemurafenib, bepeside (etopocid), beadur (leuprolide acetate), vidaza (azacitidine), vinblastine sulphate, vinblastine PFS (vincristine sulfate), vincristine sulphate, vincristine sulphate
Salt liposomes, vinorelbine tartrate, VIP, bismodegib, volaxase (glucarpidase), vorinostat, vorinostat (pazopanib hydrochloride), welcobolin (leucovorincalcium), zacoli (crizotinib), zeloda (capecitabine), XELIRI, XELOX , Zofigo (Radium Dichloride 223), Ixtanji (Enzartamide), Yervoy (Ipirimmab), Zaltrap (Ziv-Aflibercept), Zelboraf (Vemurafenib), Zevalin (Ibritumomabutiuxetan), Zaincard (Dexrazoxane Hydrochloride) , Ziv-Aflibercept, Zoladex (gocerelic acetate), Zoredronic acid, Zolinza (vorinostat), Zometa (Zoredronic acid), Zyderigu (idelaricib), Zicadia (seritinib), or Zytiga (avirateron acetate). Method.
[Invention 1032]
Inhibiting or reducing tumor cells in a subject comprising administering to the subject any bispecific antibody of the invention 1001-1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. how to.
[Invention 1033]
The number of tumor cells is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70 compared to control or reference values. %, At least about 80%, at least about 90%, or at least about 100% reduction, the method of the invention 1032.
[Invention 1034]
By cells expressing CD3 in the subject, comprising administering to the subject any bispecific antibody of the invention 1001-1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. A method of increasing the production of cytokines.
[Invention 1035]
IL-2 in said T cells comprising contacting the T cells with any bispecific antibody of the invention 1001-1017 or an antigen binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. , CD69, and / or a method of increasing the production or concentration of IFN-γ.
[Invention 1036]
IFN-γ production is at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, at least about 600%, at least about 700% compared to control or reference values. The method of the invention 1035, which increases by at least about 800%, at least about 900%, or at least about 1000%.
[Invention 1037]
IFN-γ concentration is at least about 1000 pg / ml, at least about 2000 pg / ml, at least about 3000 pg / ml, at least about 4000 pg / ml, at least about 5000 pg / ml, at least about 6000 pg / ml compared to the control or reference value. The method of the invention 1035, which increases ml, at least about 7000 pg / ml, at least about 8000 pg / ml, at least about 9000 pg / ml, or at least about 10000 pg / ml.
[Invention 1038]
CD69 production is at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least compared to control or reference values. The method of the invention 1035, which increases by about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, or at least about 30%.
[Invention 1039]
A method of stimulating an immune response in a subject comprising administering to the subject any bispecific antibody of the invention 1001-1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. ..
[Invention 1040]
T cell mediation to cancer cells in a subject comprising administering to the subject any bispecific antibody of the invention 1001-1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. A method of stimulating a sex cytotoxic immune response.
[Invention 1041]
A method for increasing T cell proliferation, comprising contacting T cells with any bispecific antibody of the invention 1001-1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. ..
[Invention 1042]
Regulatory T cells in the tumor of the subject comprising administering to the subject any bispecific antibody of the invention 1001-1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018-1027. How to reduce or deplete the number of.
[Invention 1043]
Prediction of cancer or cancer metastasis in a subject, comprising determining the expression level of MOSPD2 in a sample of subject using any of the bispecific antibodies of the present invention 1001-1017 or antigen-binding fragments thereof. A method for diagnosis or prognosis.
[Invention 1044]
(I) The bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof is used to determine or quantify the expression level of MOSPD2 in a sample of interest, and (ii) step (ii). It involves comparing the expression level obtained in i) with a control or reference value, wherein an increase in MOSPD2 expression level relative to the control or reference value is a high risk of developing cancer, cancer, or. The method of the present invention 1043, which exhibits a poor prognosis for cancer.
[Invention 1045]
Tumor progression or tumor infiltration in a subject, comprising determining the expression level of MOSPD2 in a sample of subject using any of the bispecific antibodies of the present invention 1001-1017 or antigen-binding fragments thereof. A method for prediction, diagnosis, or prognosis.
[Invention 1046]
(I) The bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof is used to determine or quantify the expression level of MOSPD2 in a sample of interest, and (ii) step (ii). It involves comparing the expression level obtained in i) with a control or reference value, wherein an increase in MOSPD2 expression level relative to the control or reference value results in poor tumor progression or tumor invasive prognosis. Shown, the method of the present invention 1045.
[Invention 1047]
The following steps:
Instruct the laboratory to quantify the expression level of MOSPD2 in the sample;
Obtain reports of MOSPD2 expression levels in the sample from the laboratory; and / or
Administering a therapeutically effective amount of a MOSPD2 inhibitor to the subject
The method of any of 1043-1046 of the present invention, further comprising one or more of.
[Invention 1048]
The method of any of 1043-1047 of the present invention, wherein the sample is a tissue biopsy, tumor biopsy, or blood sample from the subject.
[Invention 1049]
The method of any of 1043-1048 of the present invention, wherein the control or reference value is the expression level of MOSPD2 in normal tissue or normal adjacent tissue (NAT).
[Invention 1050]
The method of any of 1043-1048 of the present invention, wherein the control or reference value is either no detectable MOSPD2 expression or no significant MOSPD2 expression.
[Invention 1051]
A bispecific antibody of any of the present inventions 1001 to 1017 or an antigen-binding fragment thereof or a pharmaceutical composition of any of the present inventions 1018 to 1027 is targeted in an amount effective for treating or preventing MOSPD2-expressing tumors. A method of treating or preventing a MOSPD2-expressing tumor in a subject, comprising administration.
[Invention 1052]
The bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018 to 1027 is effective for treating or preventing a tumor having MOSPD2-expressing tumor-associated macrophages. A method of treating or preventing a tumor having MOSPD2-expressing tumor-associated macrophages in the subject, comprising administering to the subject in a large amount.
[Invention 1053]
(I) A kit comprising the bispecific antibody of the present invention 1001 to 1017 or an antigen-binding fragment thereof or the pharmaceutical composition of any of the inventions 1018 to 1027, and (ii) instructions for use.
Claims (27)
ïŒïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒããã³
ïŒïœïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é å
ã®1ã€ä»¥äžãå«ããè«æ±é 1ïœ4ã®ããããäžé ã«èšèŒã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã The following antigen-binding domains:
Any one of claims 1-4, comprising (i) one or more heavy chain variable regions of an anti-MOSPD2 antibody or antigen-binding fragment thereof; and (ii) one or more light chain variable regions of an anti-MOSPD2 antibody or antigen-binding fragment thereof. The bispecific antibody or antigen-binding fragment thereof according to the section.
ïŒïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒããã³
ïŒïœïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é å
ã®1ã€ä»¥äžãå«ããè«æ±é 1ïœ5ã®ããããäžé ã«èšèŒã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã The following antigen-binding domains:
Any one of claims 1-5, comprising (i) one or more heavy chain variable regions of an anti-CD3 antibody or antigen-binding fragment thereof; and (ii) one or more light chain variable regions of an anti-CD3 antibody or antigen-binding fragment thereof. The bispecific antibody or antigen-binding fragment thereof according to the section.
ïŒïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒ
ïŒïœïœïŒæïŒïŒ¯ïŒ³ïŒ°ïŒ€2æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é åïŒ
ïŒïœïœïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®ééå¯å€é åïŒããã³
ïŒïœïœïŒæ3æäœãŸãã¯ãã®æåçµåæçã®è»œéå¯å€é å
ãå«ããè«æ±é 1ïœ6ã®ããããäžé ã«èšèŒã®äºéç¹ç°æ§æäœãŸãã¯ãã®æåçµåæçã The following antigen-binding domains:
(I) Heavy chain variable region of anti-MOSPD2 antibody or antigen-binding fragment thereof;
(Ii) Light chain variable region of anti-MOSPD2 antibody or antigen-binding fragment thereof;
(Iii) The heavy chain variable region of an anti-CD3 antibody or antigen-binding fragment thereof; and (iv) the light chain variable region of an anti-CD3 antibody or antigen-binding fragment thereof, according to any one of claims 1 to 6. Bispecific antibody or antigen-binding fragment thereof.
ãã³ã«ãµãŒã«ïŒ°ïŒŠïŒ³ïŒãã³ã¯ãªã¹ãã³ãµã«ãã§ãŒãïŒããã³ã¯ãªã¹ãã³ç¡«é žå¡©ããã³ã¯ãªã¹ãã³ç¡«é žå¡©ãªããœãŒã ãããã¬ã«ãã³é ç³é žå¡©ãããã¹ã¢ãã®ãããã©ã¯ãµãŒãŒïŒã°ã«ã«ã«ãããŒãŒïŒãããªãã¹ã¿ããããŽã©ããªãšã³ãïŒããŸãããå¡©é žå¡©ïŒããŠã§ã«ã³ããªã³ïŒãã€ã³ããªã³ã«ã«ã·ãŠã ïŒãã¶ãŒã³ãªïŒã¯ãªãŸãããïŒããŒããŒãïŒã«ãã·ã¿ãã³ïŒããããšã¯ã¹ãžãïŒããã¹ããïŒããŸãŒãã£ãŽïŒäºå¡©åã©ãžãŠã 223ïŒãã€ã¯ã¹ã¿ã³ãžïŒãšã³ã¶ã«ã¿ããïŒãã€ãŒãã€ïŒã€ããªã ããïŒãã¶ã«ãã©ããïŒïŒºïœïœâã¢ããªãã«ã»ããïŒããŒã«ãã©ãïŒãã ã©ãã§ããïŒããŒãŽã¡ãªã³ïŒã€ããªãã¢ããããŠãã»ã¿ã³ïŒãã¶ã€ã³ã«ãŒãïŒãã¯ã¹ã©ãŸããµã³å¡©é žå¡©ïŒãïœïœâã¢ããªãã«ã»ããããŸã©ããã¯ã¹ïŒé ¢é žãŽã»ã¬ãªã³ïŒããŸã¬ããã³é žããŸãªã³ã¶ïŒããªãã¹ã¿ããïŒããŸã¡ã¿ïŒãŸã¬ããã³é žïŒãã¶ã€ããªã°ïŒã€ãã©ãªã·ãïŒããžã«ãã£ã¢ïŒã»ãªãããïŒããŸãã¯ã¶ã€ãã£ã¬ïŒé ¢é žã¢ãã©ããã³ïŒã§ãããè«æ±é 19ã«èšèŒã®å»è¬çµæç©ã The anticancer agents include avilateron acetate, abitrexate (methotrexate), abraxane (pacrytaxel albumin-stabilized nanoparticles preparation), ABVD, ABVE, ABVE-PC, AC, AC-T, ADCETRIS (brentuximabbedothin), ADE. , Adtras tsuzumabuemtancin, adriamycin (doxorubicin hydrochloride), adorsyl (fluorouracil), afatinib dimaleate, affinitol (everolims), akinzeo (netupitant and paronosetron hydrochloride), aldara (imikimod) ), Aroxy (paronocetron hydrochloride), ambochlorin (chlorambucil), amboclorin (chlorambucil), aminolevulinic acid, anastrozole, aprepitant, aredia (disodium pamidronate), arimidex (anastrozole), aromasin. (Exemestane), Alanon (Nerarabin), Arsenic trioxide, Azera (Ofatumumab), Asparaginase Erwinia chlorambucil, Avastin (Bevasizumab), Avastin (Bevasizumab), Axitinib, Azasitinib , Verinostat, Bendamstine Hydrochloride, BEP, Bebasizumab, Bexarotene, Bexal (Toshitsumomab and I 131 Iodine Toshitsumomab), Bicartamide, BiCNU (Carmustine), Breomycin, Brinatsumomab, Brynsite (Brinatumobismab), Bortezomib Tuximabubedotin, Busulfan, Busulfex (Busulfan), Cabaditaxel, Cabozantinib-S-apple salt, CAF, Campus (Alemtuzumab), Camptosar (Irinotecan hydrochloride), Capesitabin, CAPOX, Carboplatin, Carmustine-Taxol, Carmustine (Carmustine), Carmustine, Carmustine Implant, Casodex (Vicartamide), CeeNU (Romustine), Seritinib, Servisin (Doxorubicin Hydrochloride), Servisx (Recombinant HPV Bivalent Vaccine), Setuximab, Chlorambucil, Chlorambucil Mubusyl-predonison, CHOP, cisplatin, clafen (cyclophosphamide), fludarabine, CMF, cometric (cabozanthinib-S-apple salt), COPP, COPP-ABV, cosmegen (doxorubicin), crizotinib, CVP, cyclophos Famide, Cyphos (Iphosphamide), Cyramza (Ramsilmab), Citarabin, Citarabin, Liposomal, Citosar-U (Citarabin), Citoxan (Cyclophosphamide), Dabrafenib, Dacarbazine, Dacogen (decitabin), Doxorubicin, Doxorubicin Hydrochloride, decitabin, degarelix, deniroykin diphtytox, denosmab, deposite (liposomarcitarabin), depoform (liposomarcitarabin), dexrazoxane hydrochloride, dinutuximab, dosetaxel, doxil (doxorubicin hydrochloride liposome), doxorubicin hydrochloride Hydrochloride, doxorubicin hydrochloride liposomes, Dox-SL (doxorubicin hydrochloride liposomes), DTIC-Dome (dacarbazine), efdex (fluorouracil), erytec (lasbricase), elence (epirubicin hydrochloride), eroxatin (oxaliplatin), el Thrombopaguolamine, Imend (Aprepitant), Enzartamide, Epirubicin Hydrochloride, EPOCH, Arbitax (Setuximab), Elibrine Mesylate, Erivedge (Bismodegib), Elrotinib Hydrochloride, Elwinase (Asparaginase Elwinia Chrysantemi), Etopophosphamide Etoposide), Etoposide, Phosphate Etoposide, Evaset (doxorubicin hydrochloride liposome), Eberolimus, Evista (laroxyphene hydrochloride), Exemestane, Fairston (Tremiphen), Faridadack (Panobinostat), Faslodex (Fullbestland), FEC , Femara (Retrozole), Philgrastim, Fludarabine (Fludarabine Phosphate), Fludarabine Phosphate, Fluoroplex (Fluorouracil), Fluorouracil, Forex (Mettrexate), Forex PFS (Mettrexate), Forfili, Forfili-bebasiszumab, Forfili-setuximab , Forfilinox, Forflox, Forotin (Plaratrexate), FU-LV, Fludarabine, Gardacil (Recombinant HPV) (Four-valent vaccine), Gardacil 9 (recombinant HPV nine-valent vaccine), Gaziba (obinutuzumab), gemcitabine, gemcitabine hydrochloride, gemcitabine-cisplatin, gemcitabine-oxaliplatin, gemcitabine ozogamicin, gemzar (gemcitabine hydrochloride) , Geotrif (Afatinib dimaleate), Gleevec (Imatinibmesilate), Giliadel (Carmustin Implant), Giliadel Wafer (Carmustin Implant), Glucalpidase, Goseleline Acetate, Haraben (Elibrin Mesylate), Herceptin (Trastuzumab), Gem Alternate HPV bivalent vaccine, recombinant HPV nine-valent vaccine, recombinant HPV tetravalent vaccine, Hycamtin (topotecan hydrochloride), Hyper-CVAD, Ibrance (palbocyclib), Ibritzumombyuxetan, ibrutinib, ICE, Iclusig (ponatinib hydrochloride) ), Idamycin (idalbisin hydrochloride), idarubicin hydrochloride, ideralisib, ifex (iphosphamide), ifofamide, ifosfamidem (iphosphamide), imatinib mesylate, imbulbica (ibrutinib), imikimod, inwriter (axitinib), inwriter (axitinib) -2b), Iodine 131 toshitumomab and toshitsumomab, ipilimumab, iressa (gefitinib), irinotecan hydrochloride, istodax (lomidepsin), ixavepyrone, igzenpra (ixabepirone), jakafi (luxabepyrone) Emtancin), Keoxyphen (Laloxyphene Hydrochloride), Kepivans (Parifermin), Keytruda (Pembrolizumab), Kaiprolis (Carfilzomib), Lanleothide acetate, Lapatinib ditosylate, Lenalidemide, Lembatinib mesylate, Lembima (Lemcitabine mesylate) , Leucovorin calcium, leukelan (chlorambusyl), leuprolide acetate, leblanc (aminolevulinic acid), phosphoridine (chlorambusyl), lipodox (doxorbisin hydrochloride liposome), liposomarcitarabin, romstin, rupron (leuprolide acetate), ruprondepo (leuprolide acetate) Luprondepo-Ped (leuprolide acetate), Luprondepo 3-month formulation (leupronide acetate), Luprondepo 4-month formulation (acetate) Leuprolide), Lynparza (Olaparib), Marquibo (Vincristin sulfate liposome), Maturene (Procarbazine hydrochloride), Mechlormethine hydrochloride, Megeth (Megestrolexate), Megestrol acetate, Mekinist (Trametinib), Mercaptopurine, Mesna, Mesnex (Mesna), Metazolaston (Temozolomid), Methotrexate, Methotrexate LPF (Methotrexate), Mexate (Methtrexate), Mexate-AQ (Mettrexate), Mitomycin C, Mitoxanthron hydrochloride, Mitozytrex (Mitomycin C), MOPP, Mozovir (Plerixafor), Mustalgen (Methotrexate), Mutamycin (Mitomycin C), Milleran (Busulfan), Myrosal (Azacitidine), Myrotarg (Gemtuzumab ozogamycin), Nanoparticles Paclitaxel (Pacritaxel albumin stabilization) Nanoparticle formulation), navelvin (binormethine tartrate), nerarabin, neosar (cyclophosphamide), netupitant and paronosetron hydrochloride, nupogen (filgrastim), nexavar (solafenibutosylate), nirotinib, nibolumab, nolvadex (tamoxyphene) Citrate), N-plate (Lomiprostim), Obinutsumab, OEPA, Ofatumumab, OFF, Olaparib, Omasetaxin Methotrexate, Oncasper (Peguspargase), Ontac (Deniroykin difchitox), Opdivo (Nivormab), OPPA, oxaliplatin, paclitaxel, paclitaxel / albumin-stabilized nanoparticle formulation, PAD, parvocyclib, parifermin, paronosetron hydrochloride, disodium pamidronate, panitummab, panobinostat, paraplat (carboplatin), paraplatin (carboplatin), pazopanib hydrochloride , Pegua spargase, peginterferon α-2b, PEG-intron (peginterferon α-2b), pembrolizumab, pemethrexed disodium, perjeta (pelzzumab), perzzumab, platinol (cisplatin), plerixafor , Pomalidemid, Pomalist (Pomalydomido), Ponatinib hydrochloride, Pleraxate, Plermethine, Procarbazine hydrochloride, Proleukin (Al) Desroykin), Prolia (Denosumab), Promacta (Eltronbopaguolamine), Provenge (Ciploisel T), Prinetor (Mercaptopurine), Prixane (Mercaptopurine), Radium dichloride 223, Laroxyphen hydrochloride, Ramsylmab, Lasbricase, R- CHOP, R-CVP, recombinant human papillomavirus (HPV) bivalent vaccine, recombinant human papillomavirus (HPV) nine-valent vaccine, recombinant human papillomavirus (HPV) tetravalent vaccine, recombinant interferon α-2b, regorafenib, R- EPOCH, revrimid (renalidemid), rheumatrex (methotrexate), rituximab (rituximab), rituximab, lomidepsin, lomiprostim, rubidomycin (daunorbisin hydrochloride), luxolitinibphosphate, screlosyl thoracic aerosol (talxyloximab) Somatuline depot (lanleotide acetate), sorafenib tosilate, spritel (dasatinib), Stanford V, sterile talc powder (talc), steritarc (talc), stiberga (legoraphenib), sunitinib linate, sutent (sunitinib linate) ), Silatron (Peginterferon α-2b), Sylvanto (Siltuximab), Sinobeal (Salidomid), Synribo (Omasetaxin mepesuccinate), TAC, Tafinlar (Dabrafenib), Tarku, Tamoxyphencitrate, Tarabin PFS (Citarabin) , Tarceva (erlotinib hydrochloride), targretin (bexarotene), tasigna (sunitinib), taxol (pacritaxel), taxotere (docetaxel), temodar (temozolomid), temozolomid, temsirolimus, salidomid , Topotecan Hydrochloride, Tremiphen, Torisel (Temcilolimus), Toshitumomab and I131 Iodine Toshitsumomab, Totect (Dexrazoxane Hydrochloride), TPF, Tramethinib, Trastuzumab, Treanda (Bendamstin Hydrochloride), Trisenox (Hydetrioxide), Tykelb Acid Lapatinib), Unituxin (Zinutuximab), Bandetanib, VAMP, Vectibix (Panitumumab), VeIP, Velvan (Bimblastin Sulfate), Velcade (Voltezomib), Berser Lu (vinblastine sulphate), vemurafenib, bepeside (etoposide), beadur (leuprolide acetate), vidaza (azacitidine), vinblastine sulphate,
Vincristine PFS (vincristine sulfate), vincristine sulfate, vincristine sulfate liposomes, vincristine tartrate, VIP, bismodegib, voraxase (glucarpidase), vorinostat, vorinostat (pazopanib hydrochloride), welcobolin (leucovorincalcium), zakoborin (leucovorincalcium) Xeloda (capesitabin), XELIRI, XELOX, Exdiva (denosmab), Zofigo (radium dichloride 223), Xtanji (enzartamide), Yervoy (ipilimmab), Zaltrap (Ziv-aflibercept), Zelboraf (vemurafenib), Zevalin (Evemurafenib). Ritzmoma butyuxetane), Zaincard (dexrazoxane hydrochloride), Ziv-aflibercept, Zoladex (gocerelic acetate), zoredronic acid, zorinza (vorinostat), zometa (zoredronic acid), zyderigu (idelaricib), dicadia (seritinib), The pharmaceutical composition according to claim 19 , which is Zytiga (avilateron acetate).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862642339P | 2018-03-13 | 2018-03-13 | |
US62/642,339 | 2018-03-13 | ||
PCT/IB2019/052049 WO2019175806A1 (en) | 2018-03-13 | 2019-03-13 | Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021517153A JP2021517153A (en) | 2021-07-15 |
JP2021517153A5 JP2021517153A5 (en) | 2021-09-02 |
JPWO2019175806A5 true JPWO2019175806A5 (en) | 2022-03-22 |
Family
ID=67907532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020549031A Pending JP2021517153A (en) | 2018-03-13 | 2019-03-13 | Bispecific antibody against MOSPD2 and T cell or NK cell specific molecule Refer to electronically filed sequence listing |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200407434A1 (en) |
EP (1) | EP3765490A4 (en) |
JP (1) | JP2021517153A (en) |
KR (1) | KR20200143385A (en) |
CN (1) | CN112041336A (en) |
AU (1) | AU2019235652A1 (en) |
CA (1) | CA3093633A1 (en) |
IL (1) | IL277283A (en) |
WO (1) | WO2019175806A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11697682B2 (en) | 2020-09-10 | 2023-07-11 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 antibodies and methods of use thereof |
WO2024020537A2 (en) * | 2022-07-22 | 2024-01-25 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2861031C (en) * | 2012-02-03 | 2022-10-25 | Carole BOURQUIN | Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine |
EP2769989A1 (en) * | 2013-02-21 | 2014-08-27 | UniversitÀtsklinikum Freiburg | Recombinant bispecific antibody that binds to the CD133 antigen on tumor cells and to the human CD3 T cell receptor |
SI3221356T1 (en) * | 2014-11-20 | 2021-01-29 | F. Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules against folr1 and cd3 |
MX2017014699A (en) * | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Novel polypeptides. |
EP3328401B1 (en) * | 2015-07-31 | 2020-10-14 | Vascular Biogenics Ltd. | Motile sperm domain containing protein 2 and cancer |
-
2019
- 2019-03-13 WO PCT/IB2019/052049 patent/WO2019175806A1/en unknown
- 2019-03-13 US US16/980,659 patent/US20200407434A1/en not_active Abandoned
- 2019-03-13 AU AU2019235652A patent/AU2019235652A1/en active Pending
- 2019-03-13 JP JP2020549031A patent/JP2021517153A/en active Pending
- 2019-03-13 KR KR1020207029245A patent/KR20200143385A/en unknown
- 2019-03-13 EP EP19767205.8A patent/EP3765490A4/en active Pending
- 2019-03-13 CN CN201980028421.6A patent/CN112041336A/en active Pending
- 2019-03-13 CA CA3093633A patent/CA3093633A1/en active Pending
-
2020
- 2020-09-10 IL IL277283A patent/IL277283A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102486055B1 (en) | Paclitaxel-albumin-binder compositions and methods of use and preparation thereof | |
TWI828673B (en) | Vista antigen-binding molecules | |
EP3328425B1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
JP7118331B2 (en) | HER3 antigen binding molecule | |
WO2021048274A1 (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
JP2018527333A5 (en) | ||
TW201707725A (en) | Carrier-antibody compositions and methods of making and using the same | |
JP2021518380A (en) | High affinity neutralizing monoclonal antibody against programmed cell death ligand 1 (PD-L1) and its use | |
JP2020523414A (en) | Antibody drug conjugates that bind to LGR5 | |
EP3768325A1 (en) | Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate | |
US20200407434A1 (en) | Bispecific antibodies to mospd2 and t cell- or nk cell-specific molecules | |
JPWO2019175806A5 (en) | ||
KR20220133996A (en) | Combination therapy to treat cancer and cancer metastasis | |
RU2801828C2 (en) | Combination therapy with semaforin 4d (sema4d) blocking and dc1 therapy | |
US20240058464A1 (en) | Combination therapy with for46 for cancer | |
WO2022263388A1 (en) | Cells expressing vista antigen-binding molecules | |
WO2024062073A1 (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
WO2023201375A2 (en) | Cdrs for glycosylated acat1 | |
TW202328196A (en) | Treatment and prevention of cancer using vista antigen-binding molecules | |
AU2022375806A1 (en) | Lag-3 antagonist therapy for hematological cancer | |
WO2020044252A1 (en) | Dosage regimes for anti-m-csf antibodies and uses thereof |